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1.1 Background and aim of the study 
 
Since the 1960s, microtubule targeting agents (MTA) have become the most successful 
and effective chemotherapeutic agents used in the clinic today. They are effective well 
below their maximum tolerated dose (MTD) and are used as single agents or in 
combination for the treatment of a variety of hematological malignancies and solid 
tumors.1 Their success is based on the fact that they target microtubules, which are 
essential components of the cytoskeleton and play important roles in regulating mitosis, 
cell shape, trafficking, signaling and motility.2 Depending on their way of action, MTAs can 
be divided into two classes: microtubule stabilizers and destabilizers.3 In the last years it 
became increasingly evident that the antitumor effects of MTAs not only rely on their 
ability to interfere with the mitotic spindle apparatus and to provoke tumor cell death, but 
also show promising anti-metastatic, anti-angiogenic and vascular disrupting effects.4 
The latter is mediated by a relatively new group, called vascular disrupting agents (VDAs). 
These agents target, in contrast to the classic angiogenic inhibitors (AI), the already 
established tumor vasculature of larger solid tumors and selectively induce tumor vessel 
collapse, stop of blood flow and central necrosis.5 In recent years, natural compounds of 
the destabilizing MTA class were the most successful VDAs. Among them, combretastatin 
A-4-phosphate (CA-4-P), the most famous and intensively investigated VDA, which was 
originally isolated from the African tree Combretum caffrum,6 is currently in clinical trial 
phase III.7 Despite their promising anti-tumor properties, the efficiency of VDAs is limited 
due to certain side-effects and drug resistance.8, 9 To circumvent these obstacles it is 
important to expand the pool of VDAs by identifying new compounds. Hereby natural 
sources like plants, bacteria or fungi, which produce a high diversity of compounds 
suitable as lead structures, represent a very promising option, however, poor accessibility 
is still a major challenge.  
In 2009, pretubulysin (PT), a natural compound of myxobacterial origin (Angiococcus 
disciformis), was first synthesized in gram scale by Ullrich et al.10, 11 It represents a 
biosynthetic precursor of the microtubule depolymerizing tubulysins,12 which recently 
showed high activity against different tumor cell lines.13, 14 PT is like tubulysin, a linear 
tetrapeptide, but its structure is less complex, making them synthetically more easily 
accessible. Since PT is able to depolymerize microtubules nearly in the same potency as 
tubulysin and shows profound anti-tumor as well as anti-angiogenic properties,15, 16 we 
hypothesized that PT could act as a new VDA. 
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The aims of the study were: 
I. to clarify if PT is able to induce typical features of vascular disruption in vitro and 
in vivo and 
II. to elucidate the underlying signaling pathway induced by PT in endothelial cells. 
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1.2 Natural compounds 
1.2.1 Importance of natural compounds 
Natural products produced by plants and microbes have played an essential role in drug 
discovery.17 Due to their high chemical diversity and their biological history, they offer an 
enormous source of potential new therapeutic agents, either as lead structure or directly. 
Today many natural products are tested in clinical trials against several malignancies.18 In 
recent years, myxobacteria have gained importance since they are great producers of a 
variety of secondary metabolites with different biological activities and modes of action.19 
The most promising anti-cancer agents isolated from myxobacteria are the microtubule-
binders epothilones and tubulysins.13, 18 
1.2.2 Myxobacteria as producers of natural compounds 
Myxobacteria belong to the group of gram-negative δ-proteobacteria, which occupy a wide 
range of habitats including soil, decomposing plant materials and the bark of trees.20 They 
are characterized by special behaviors that differentiate them from other bacteria: i) They 
move by gliding or creeping over the surface and produce several extracellular enzymes 
for food digestion. ii) They typically build swarms of many cells, kept together by 
intercellular signal molecules and in case of scarce resources (e.g. starvation conditions) 
they aggregate into fruiting bodies21 (Figure 1 A-C). iii) Their genomes are very large, thus 
producing an enormous variety of secondary metabolites (e.g. Sorangium cellulosum with 
20 and Myxococcus xanthus with 18 gene clusters).22, 23 Reichenbach and Höfle24 were 
the first describing this variety and opened up the field for new natural compounds with 
new chemical structures and modes of action.19 
Figure 1 Typical fruiting bodies of myxobacteria. A: Myxococcus xanthus (www.wikipedia.de)  
B: Chondromyces apiculatus (www.sciencedirect.com) C: Stigmatella aurantiaca (www.sciencedirect.com). 
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1.2.3 The myxobacterial compound pretubulysin 
In the present work, the myxobacterial compound pretubulysin (PT) was intensively 
investigated concerning its vascular disrupting activity. PT was first isolated from 
Angiococcus disciformis An d48 in very small amounts.12 It is a biosynthetic precursor of 
the microtubule depolymerizing tubulysins,12 which have recently been described to be 
highly active against different tumor cell lines.13, 14 Structurally, PT is a linear tetrapeptide 
consisting of N-methylpipecolic acid (Mep), isoleucine (Ile), tubuvaline (Tuv) and either 
tubuphenylalanine (Tup) or tubutyrosine (Tut) (Figure 2). In contrast to tubulysins, PT 
lacks the acetoxy group and the N,O-acetal functionality,12 which makes PT synthetically 
more easily accessible compared to tubulysin.25-28 In 2009, PT was first synthesized in the 
gram scale by Ullrich et al.10, 11 and although the structure of PT is less complex, it shows 
nearly the same microtubule depolymerizing potency as tubulysin and is also able to 
inhibit tumor cell growth.15 
Figure 2 Pretubulysin and the proposed biosynthetic pathway to the nine known tubulysins. 
Adapted according to Ullrich et al.11 
1.3 The microtubule system 
The eukaryotic cytoskeleton is composed of three distinct elements: actin microfilaments, 
intermediate filaments and microtubules. The latter represent a dynamic system, which is 
critically important for the spatial and temporal organization of eukaryotic cells. 
Microtubules are involved in many cellular functions such as intracellular transport, 
organelle positioning, cell migration and polarization, signaling and cell division.  
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1.3.1 Structure of microtubules 
Microtubules are hollow tube-like structures of about 24 nm in diameter comprised of 
heterodimers of α- and β-tubulin (each 55 kDa). Both tubulin subunits alternately (head to 
tail) build longitudinal and lateral contacts to form the main element of microtubules, the 
protofilament (Figure 3). In vivo 13 parallel offset protofilaments build the helical 
microtubule, whereby the remarkable organization of tubulin heterodimers results in a 
polarized microtubule, consisting of a (+)-end (β-tubulin) and a (-)-end (α-tubulin). The 
polymerization of α- and β-monomers depends on guanosine triphosphate (GTP), which 
binds to its GTP-binding site at the N-terminal domain of α- and β-subunits. The α-tubulin 
subunit only binds GTP at the dimer interface and it is never hydrolyzed or exchanged, 
whereas β-tubulin binds both, GDP and GTP.29 Microtubules are anchored via their 
(-)-ends at the MTOC, which is located at the perinuclear region and is also known as 
centrosome. It consists of two centrioles and proteins which are important for microtubule 
anchoring and organization. One of them, the γ-tubulin, associates with other proteins to 
form the γ-TuRC (Tubulin Ring Complex), thus promoting αβ-heterodimer binding and 
microtubule nucleation (Figure 3).30 
Figure 3 Structure of microtubules. Modified according to Jordan and Wilson.3 
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1.3.2 Dynamic microtubules – mode of action 
Polymerization of microtubules occurs in two steps: a slow nucleation and a rapid 
elongation, thereby adding reversible and non-covalent GTP-bound tubulin dimers to the 
microtubule lattice.3 GTP-bound β-tubulin is hydrolyzed to GDP and Pi upon assembly, 
thus forming a GTP or GDP-Pi cap. In the presence of the cap, microtubules are stabilized 
and can grow. GTP hydrolysis and Pi dissociation result in conformational changes of 
tubulin leading to a reduced binding affinity of neighboring subunits in the polymer. As a 
consequence, the unstable microtubule core is exposed and depolymerizes rapidly 
(Figure 4).31 
Figure 4 Polymerization and depolymerization of microtubules. Adapted according to Jordan and 
Wilson.3 
Microtubules always switch between polymerization and depolymerization, a process 
called dynamic instability.32, 33 Thereby, the individual microtubules ends undergo phases 
of growth and shortening. The (+)-ends shortens and grows more rapidly than the (-)-
ends, which are capped by the γ-TuRC and embedded in the MTOC. A further dynamic 
behavior called ‘treamilling’ represents the net growth at one microtubule end and 
simultaneously shortening at the other end.34 Thereby, tubulin subunits from the (+)-end 
flow to the (-)-end. This process has been shown to occur mainly during metaphase and 
anaphase.35 Dynamic instability and treatmilling are not strictly separated; they even occur 
in some microtubules at the same time and depend on post-translational modifications 
and regulatory proteins.36, 37  
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1.3.3 Regulation of microtubule dynamics 
Microtubules dynamics, properties and spatial distribution are strictly regulated and 
depend on different tubulin isoforms, post-translational modifications and microtubule 
associated proteins (MAPs). Today six α-tubulin and seven β-tubulin isoforms, varying in 
different tissues and cells, are known.31 They undergo tyrosination, detyrosination, 
acetylation, polyglutamylation, polyglycylation, phosphorylation, and palmitoylation to 
achieve complete activity, however, they are not directly involved in determining the 
dynamic properties of microtubules.38 In contrast, MAPs directly interact with microtubule 
dynamics and mediate either stabilization (e.g. MAP4, tau) by favoring their 
polymerization, or destabilization (e.g. stathmin, kinesin-13 family) by sequestering tubulin 
heterodimers and promoting depolymerization.2 
1.3.4 Natural products that target microtubules 
Since microtubules are involved in many important cellular processes, especially in cell 
division and motility, they represent the major target in cancer chemotherapy identified so 
far.3 Many chemically diverse substances, originating from several natural sources 
(Table 1) are known to bind to tubulin, thereby acting as anti-mitotic, anti-proliferative or 
apoptosis inducing agents.39 Besides their effects in cancer cells, some of them also show 
anti-angiogenic (taxanes, Vinca alkaloids, epothilones and tubulysins) and anti-vascular 
properties (combretastatins, NPI-2358) in tumor endothelial cells.39  
Table 1  Several important MTAs of different natural sources 
Origin Drug Microtubule binding site 
Plant Combretastatins (CA-4P, CA-1P, 
AVE8062) 
Colchicine-binding site 
 Paclitaxel (Taxol) Taxane-binding site 
 Docetaxel (Taxotere) Taxane-binding site 
 Colchicine and ZD6126 Colchicine-binding site 
 
Vinca alkaloids (Vincristine, 
Vinblastine, Vinflunine) Vinca-binding site 
 Taccalonolides Taxane-binding site 
Bacterial Epothilones Taxane-binding site 
 Tubulysins Vinca-binding site 
Fungi NPI-2358 Colchicine-binding site 
 Phomopsin Vinca-binding site 
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Table 1  Continued 
Origin Drug Microtubule binding site 
Marine Hemiasterlins Vinca-binding site 
 Laulimalide Taxane-binding site 
 Pelorusides Taxane-binding site 
 Halichondrins Vinca-binding site 
 Dolastatins Vinca-binding site 
 Spongistatins Vinca-binding site 
 
Microtubule targeting agents (MTAs) bind to different binding sites on tubulin, thereby 
varying in affinity, reversibility and microtubule impact. MTAs are classified into two major 
groups, the microtubule stabilizers, which bind to the ‘taxol’-binding site and inhibit 
depolymerization, and the microtubule destabilizers, which bind to the ‘Vinca’- or 
‘colchicine’-binding domain, thereby inducing depolymerization (Figure 5, Table 1). 
Figure 5 MTA binding sites on microtubules. A, B: Binding of MTAs to the Vinca-binding site at the 
(+)-end or colchicine-binding site within the microtubule lattice leads to depolymerization. C: MTA binding to 
the taxol-binding side at the inner surface of the microtubule stabilizes and inhibits depolymerization. Modified 
according to Jordan and Wilson.3 
1.3.5 The big problem – resistance to MTAs 
Resistance to chemotherapy with MTAs is a huge disadvantage in the combat against 
cancer. It is often caused by an overexpression of a class of membrane transporter 
proteins known as ABC-transporters (ATP-dependent drug efflux pumps or ATP-binding 
cassettes). These membrane pumps decrease the intracellular drug concentration, 
thereby reducing activity, and lead to cross-resistance (multidrug resistance, MTR) to 
drugs of different chemical structure. The first and most prominent known ABC-transporter 
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was P-glycoprotein.40 Additionally, overexpression of one of the isotypes of βIII-tubulin41 
and changes in expression levels of MAPs (e.g. stathmin, MAP2,4 and tau) or mutations 
in α-tubulin42, 43 were observed for vincristine and paclitaxel resistant cancer cells. 
Furthermore, changes of post-translational modifications at the carboxy-terminal domain 
of β-tubulin44 and also alterations in the actin cytoskeleton, especially down-regulation of 
γ-actin, was found in vincristine resistant cancer cell lines.45, 46 Since there are so many 
parameters involved in MTA resistance, the challenge will be to find new drugs, which are 
able to circumvent these obstacles.  
1.4 Anti-vascular strategies for tumor treatment 
It is well known that a functional network of blood vessels is essential for the growth, 
development and metastasis of solid tumors. While smaller tumors (< 2 mm) receive their 
oxygen and nutrients through diffusion from the surrounding tissue, bigger tumors must 
develop an angiogenic phenotype to ensure the oxygen and nutrient supply they need.47 
The proliferation rate of endothelial cells forming tumor vessels is much higher than 
compared to normal adult tissue,48, 49 which results in abnormal vessel structure and 
function in almost all aspects.50, 51 Therefore, it is not surprising that targeting the tumor 
vasculature offers an interesting anti-tumor strategy, which has been intensively explored 
in recent years. 
1.4.1 ‘Normal’ vasculature vs. tumor vasculature 
The ‘normal’ (healthy) vasculature is arranged in a hierarchy of evenly spaced, well 
differentiated arteries, arterioles, capillaries, venules and veins, which are lined by the 
vascular endothelium. The blood flow is directed (arteries to veins) and all vessels are 
perfused. The vasculature consists of a luminal front directed to the plasma and 
connected to a basement membrane and an abluminal front, which is embedded into the 
glycocalyx (polysaccharide rich layer) surrounded by stabilizing fibroblasts, smooth 
muscle cells and the interstitial fluid (Figure 6 A). The primary function of the endothelial 
barrier is to separate the inner space of the blood vessel from the surrounding tissue, 
however, its functions as size-selective- and semipermeable barrier are important to 
control the exchange of cells, fluids and solutes into the surrounding tissue.52 This so 
called vascular permeability is strictly regulated. Under physiological conditions, 
macromolecules (> 3 nm) pass the endothelial barrier transcellularly via caveolae 
mediated endocytosis or via vacuole-vesicular organelles. Molecules < 3 nm in diameter 
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use the paracellular pathway, which is mediated by the coordinated opening and closing 
of interendothelial cell junctions (IEJ; adherens (AJ) and tight (TJ) junctions).53 Among 
AJs, vascular endothelial (VE)-cadherin is exclusively expressed in vessels and the most 
important transmembrane protein in barrier regulation.54 Its extracellular domain depends 
on Ca2+ and allows homophilic interaction between two endothelial cells (ECs), whereas 
its intracellular domain is connected via α-, β-, γ- and p120-catenins to the actin 
cytoskeleton, providing an important link between actinomyosin contraction, VE-cadherin 
mediated gap formation and increased permeability. Hence, endothelial barrier function 
depends on both, structural and functional properties of the vasculature.  
In contrast to ‘normal’ vasculature, tumor vasculature is immature and shows no classic 
hierarchy known from normal tissue. The tumor vasculature is tortuous and unevenly 
distributed throughout the tumor with irregular vessel diameter, excessive branching, 
arteriovenous shunts and blind ending vessels (Figure 6 B).55 The blood flow is sluggish 
and not all open vessels are continuously perfused, which results in hypoxic and acidic 
regions.55, 56 Even the structure of tumor vessels is abnormal. They are dilated, have 
sparsely developed vessel walls with poor expression of vascular smooth muscle cells 
and poor connections between pericytes and EC.5, 57, 58 Furthermore, they have an 
irregular and structurally abnormal basement membrane.59 Tumor EC are often irregularly 
shaped and express faint VE-cadherin accompanied by loose cell-cell connections and 
intercellular openings, which contribute to hyperpermeability and high interstitial fluid 
pressure (IFP).60-62 In summary, compared to ‘normal’ vasculature, tumor vasculature is 
extremely leaky and not restrictive; meaning the function of a selective barrier is lost.  
Figure 6 Structure of ‘normal’ vasculature vs. tumor vasculature. A: Normal vasculature. B: Tumor 
vasculature. BM: Basal membrane, EC: Endothelial cell, IEJ: Interendothelial junctions, IFP: Interstitial fluid 
pressure.  
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1.4.2 Angiogenesis inhibitors and vascular disrupting agents 
Today there are two opposing anti-vascular approaches in clinical trials that show 
promising anti-tumor properties. Both differ in their treatment schedule and their way of 
action on their physiological target, the endothelium. The first group comprises the classic 
angiogenesis inhibitors (AI; e.g. bevacizumab or sorafenib), which are administered 
chronically and act on the periphery of small tumors preventing neovascularization (Figure 
7 A).63 The second group, called vascular disrupting agents (VDAs), acts in a complete 
different way to AIs. VDAs are administered acutely and they selectively target the already 
established tumor blood vessels of larger solid tumors.63-65 As a consequence, either 
direct apoptotic cell death or cytoskeletal rearrangements occur, which alter the 
endothelial cell shape.66, 67 These events emerge particularly in the central part of the 
tumor, leading to a rapid stop of blood-flow and central necrosis, which can extend to as 
much as 95% of the tumor mass (Figure 7 B).68-72 Since they are effective well below their 
maximum tolerated dose, and lack the classic cytotoxic side effects of chemotherapeutics, 
they gain importance in anti-tumor treatment.70, 73 
 
Figure 7 Anti-vascular strategies for tumor treatment. A: Angiogenesis inhibitors (AI) act on the 
periphery of tumors and prevent neovascularization. B: Vascular disrupting agents (VDAs) act on established 
tumor blood vessels in the central part of the tumor leading to necrosis.  
1.4.3 Classes of VDAs 
VDAs are divided into two classes, ligand-directed VDAs and small molecule agents 
(Figure 8). Ligand-directed VDAs are composed of targeting and effector moieties that are 
linked together usually via peptide bonds or chemical cross-linkers. They use antibodies, 
peptides or growth factors, which are coupled to pro-coagulants or toxins and selectively 
bind to targets on the tumor endothelium, leading to vessel occlusion.73, 74 Small molecule 
agents are further subdivided into synthetic flavonoids and tubulin binding agents. The 
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latter bind to β-tubulin near the colchicine or vinca-binding side, resulting in the 
depolymerization of endothelial microtubules.75 Flavonoid VDAs act in a tubulin-
independent manner and trigger vascular shutdown either directly by inducing apoptosis, 
or indirectly by inducing local cytokine production, e.g. of tumor necrosis factor α (TNFα) 
via activation of nuclear factor κB (NFκB) signaling.76-78 Since PT is a known microtubule 
depolymerizer (see 1.2.3), we aimed to elucidate its potential as a new small molecule 
VDA in this study. 
Figure 8 Classes of VDAs. 
1.4.4 Mode of action of microtubule targeting VDAs 
Despite the fact that certain microtubule targeting VDAs (e.g. CA-4-P, CA-1-P and 
AVE8062) have entered clinical trials, the precise mechanisms leading to the fast 
shutdown of tumor blood flow (within 30 min)72 are not fully understood today. 
Mechanisms in terms of vessel impairment in vitro and in vivo have as yet only been 
described for combretastatin A4-phosphate (CA-4-P; isolated from the African bush willow 
tree Combretum caffrum), which represents the lead VDA and has already entered clinical 
trial phase III in anaplastic thyroid cancer.7  
1.4.4.1 Effects on tumor vasculature 
The proposed way of action is shown in Figure 9. Upon injection, the VDA (e.g. CA-4-P) 
enters ECs from the luminal side of the vasculature and binds to microtubules (step 1). 
This causes microtubule depolymerization, which triggers actin stress fiber formation and 
EC contraction. As a consequence, IEJ are disassembled and interendothelial gabs are 
formed (step 2), which contribute to increased permeability (step 3). The loss of the 
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endothelial barrier function and the concomitant protein leakage reduces the oncotic 
pressure differential between the inside and outside of blood vessels, thus disturbing the 
water balance and cause a transient increase in interstitial fluid pressure (IFP; step 4), 
which provoke vessel occlusion (step 5). In addition, a rapid and direct vasoconstrictive 
effect on tumor supplying arterioles and a decrease in longitudinal pressure differential 
along the vessel further facilitate the reduction in blood flow. The loss of fluid increases 
blood viscosity and red cells get stacked (step 6). As a consequence, vessel perfusion is 
disturbed, leading to a deficient supply of oxygen and nutrients followed by tumor necrosis 
(step 7).5 
Figure 9 Proposed mechanism leading to rapid vascular shutdown upon treatment with CA-4-P. 
EC: Endothelial cell, IFP: Interstitial fluid pressure, VDA: Vascular disrupting agent. Modified according to 
Tozer et al.5 
 
1.4.4.2 Effects on tumor EC 
The signal process that controls vascular permeability in ECs is highly complex and the 
modulation varies under different stimulatory conditions. In case of microtubule binding 
VDAs, the depolymerization of microtubules is assumed to be the starting point of the 
signal cascade and triggers a very rapid (within minutes) change in the morphology of 
ECs (Figure 10). This goes along with the remodeling of the actin cytoskeleton and the 
appearance of focal adhesions.67 Upon microtubule depolymerization, the small GTPase 
RhoA and its downstream effector Rho kinase (ROCK) are activated. The underlying 
molecular mechanism is not exactly known, but it is suggested that guanine nucleotide 
exchange factors (GEFs) are released from disrupted microtubules, thus activating 
inactive RhoA.79 ROCK phosphorylates the myosin light chain (MLC), which in turn leads 
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to actinomyosin contraction and to the formation of actin stress fibers. The contractility 
causes an increased centripedal tension and, consequently, IEJs (especially VE-
cadherin), which is connected to the actin cytoskeleton (see 1.4.1) are disassembled.80 As 
a result vascular permeability increases and promotes the subsequent steps described 
above (1.4.4.1, Figure 9).  
In addition to the activation of RhoA, ROCK and MLC, microtubule binding VDAs activate 
the mitogen activated protein kinase (MAPK) p38 (Figure 10).80 Together with the 
actinomyosin contraction, p38 MAPK triggers an process called membrane blebbing. 
Hereby cells round up, F-actin accumulates in surface blebs building a spherical network 
that surrounds the cytoplasm, and focal adhesions appear malformed.80 Membrane 
blebbing contribute to the breakdown of the endothelial barrier and represents an early 
phenotype of a rapid necrotic cell death, separate from the apoptotic pathway triggered by 
caspases.80 
Figure 10 Signal pathway in ECs leading to barrier breakdown and vascular disruption.  
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1.4.5 Limitations of VDAs 
After VDA treatment a viable peripheral rim of tumor cells remains (see 1.4.2; Figure 7 B), 
which is responsible for the rapid regrowth after a single-dose treatment.67, 81 A common 
explanation for this typical VDA phenomenon is that tumor endothelial cells in the center 
are more accessible to VDAs, possibly due to their different morphology and the occurring 
high interstitial fluid pressure, which contribute to vessel occlusion when permeability 
increases, whereas it is tolerated at the periphery (see 1.4.1; Figure 6 B).5, 73 Moreover, 
tumor blood vessels at the periphery receive their oxygen and nutrients from the 
surrounding healthy tissue and are therefore morphologically ‘normal’ and resistant to the 
effects of VDAs.5 To overcome this resistance and the typical failure of tumor growth delay 
after a single dose, VDAs are usually combined with classic chemotherapy,49, 82-84 
radiation,69, 85, 86 radioimmunotherapy87, 88 or AI in preclinical and clinical trials.89 The 
combination therapy enhances antitumor efficiency of VDAs; e.g. co-treatment with 
radiation allows two different approaches to act in a complementary and synergistic 
manner. The VDA acts on the central hypoxic and radio-resistant part of the tumor, 
whereas the radiation acts on the tumor endothelial cells forming the outer viable rim and 
promotes suppression of regrowth. Thereby, scheduled treatment and the succession of 
VDA application are very important to obtain tumor control.83-85 Currently, there are 
several VDAs in clinical studies under intensive investigation, working as single agents or 
in combination.9 Documented side effects include acute coronary and other 
thrombophlebitic syndromes, variance in blood pressure, heart rate, and conduction, 
transient flush and hot flashes, neuropathy, ataxia, and tumor pain.90 Hence, close 
monitoring of cardiovascular toxicity is essential.  
 
 
 2 MATERIALS AND METHODS 
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2.1 Materials 
2.1.1 Compounds 
Pretubulysin (PT) was synthesized as described previously11 and was kindly provided by 
Prof. Dr. U. Kazmaier (Saarland University, Saarbrücken, Germany). Combretastatin A-4 
phosphate (CA-4-P) was a kind gift from OXiGENE (Waltham, MA, USA). Both 
compounds were stored as 10 mM stock solutions in 100% DMSO. Since in all in vitro 
experiments the final DMSO concentration did not exceed 0.1%, side effects in 
experimental settings could be excluded. 
Figure 11 Chemical structure of pretubulysin (A) and combretastatin A-4-phosphate (B) 
 
2.1.2 Biochemicals, dyes, inhibitors and cell culture reagents 
Table 2  Biochemicals and dyes 
Reagent Producer 
Accustain® paraformaldehyde Sigma-Aldrich, Taufkirchen, Germany 
BC Assay reagent Interdim, Montulocon, France 
Bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen, Germany 
Bradford Reagent™ Bio-Rad, Munich, Germany 
Cell-Titer Blue™ Reagent  Promega, Madison, WI, USA 
Coomassie brilliant blue G250 Carl Roth, Karlsruhe, Germany 
DMSO AppliChem, Darmstadt, Germany 
EGTA-K AppliChem, Darmstadt, Germany 
FluorSave™ Reagent mounting medium Merck, Darmstadt, Germany 
Formaldehyde, 16% ultrapure Polysciences Europe GmbH, Eppelheim, 
Germany 
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Table 2  Biochemicals and dyes continued 
Reagent Producer 
Glutaraldehyde Merck, Darmstadt, Germany 
Histamine Sigma-Aldrich, Taufkirchen, Germany 
Matrigel™ BD Biosciences, Heidelberg, Germany 
Non-fat dry milk powder (Blotto) Carl Roth, Karlsruhe, Germany 
Page Ruler™Prestained Protein Ladder Fermentas, St. Leon-Rot, Germany 
Propidium iodide Sigma-Aldrich, Taufkirchen, Germany 
Roti-Quant® Carl-Roth, Karlsruhe, Germany 
Triton X-100 Merck, Darmstadt, Germany 
Tween® 20 BDH/Prolabo®, Ismaning, Germany 
 
All other used biochemicals and dyes were obtained from Sigma-Aldrich, AppliChem, Carl 
Roth or Merck. 
Table 3  Inhibitors 
Inhibitor Producer 
Aprotinin Sigma-Aldrich, Taufkirchen, Germany 
Complete® mini EDTA free Roche diagnostics, Penzberg, Germany 
Leupeptin hemisulfate salt Sigma-Aldrich, Taufkirchen, Germany 
ML-7 Enzo Life Sciences, Lörrach, Germany 
Na3VO4  ICN Biomedicals, Aurora, OH, USA 
NaF  Merck, Darmstadt, Germany 
Phenylmethylsulfonyl fluoride (PMSF)  Sigma-Aldrich, Taufkirchen, Germany 
SB203580  Calbiochem, Nottingham, UK 
SP600125  Sigma-Aldrich, Taufkirchen Germany 
Y-27632 Cayman Chemical, Ann Arbor, MI, USA 
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Table 4  Cell culture reagents 
Reagent Producer 
Amphotericin B 250 µg/ml AppliChem, Darmstadt, Germany 
Collagen G Biochrom AG, Berlin, Germany 
Collagenase A Roche, Mannheim, Germany 
Dulbecco’s modified Eagle’s medium 
(DMEM) Sigma-Aldrich, Taufkirchen, Germany 
Endothelial Cell Growth Medium (ECGM) 
with Supplement Mix  #C-39215 PromoCell, Heidelberg, Germany 
FCS gold  PAA Laboratories, Pasching, Austria 
FCS PAN Biotech, Aidenbach, Germany 
M199 medium PAA Laboratories, Pasching, Austria 
Penicillin/Streptomycin 100x PAA Laboratories, Pasching, Austria 
RPMI 1640 PAN Biotech, Aidenbach, Germany 
Trypsin PAN Biotech, Aidenbach, Germany 
EDTA disodium salt dihydrate Carl Roth, Karlsruhe, Germany 
2.2 Cell culture 
2.2.1 Buffers, solutions and reagents 
The following buffers, solutions and reagents were used for the isolation as well as for the 
cultivation of endothelial cells: 
Table 5  Cell culture buffers 
PBS (pH 7.4) 
 
PBS+ Ca2+/Mg2+ (pH 7.4) 
NaCl  123.3 mM NaCl 136.9 mM 
Na2HPO4 10.4 mM  KCl 2.7 mM 
KH2PO4 3.2 mM  Na2HPO4 8.1 mM 
H2O   KH2PO4 1.5 mM 
   MgCl2 0.5 mM 
   CaCl2 0.7 mM 
   H2O  
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Table 6  Cell culture solutions 
Endothelial Cell Growth Medium 
 
Stopping medium 
ECGM  500 ml M199 500 ml 
Supplement Mix #C-39215 23.5 ml  FCS 50 ml 
FCS gold 50 ml    
Amphothericin B  
(250 µg/ml) 5 ml     
Penicillin (10,000 U/ml)/ 
Streptomycin (10 mg/ml) 5 ml    
 
DMEM 
 
B16-F1 Cell Growth Medium 
DMEM  10 g DMEM 500 ml 
NaHCO3 0.85 g  FCS (not heat-inactivated) 50 ml 
HEPES 6 g    
Amphothericin B 
(250 µg/ml) 5 ml    
Penicillin (10,000 U/ml)/ 
Streptomycin (10 mg/ml) 10 ml    
H2O ad 1000 ml    
 
A-Mel-3 Cell Growth Medium 
 
Freezing medium 
RPMI  500 ml FCS gold 50% 
FCS 50 ml  DMSO 8% 
Penicillin (10,000 U/ml)/ 
Streptomycin (10 mg/ml) 10 ml  Growth medium  
NaHCO3 1 g    
 
Trypsin/EDTA 
 
Collagen G 
Trypsin 0.05% Collagen G 0.001% 
EDTA 0.02%  PBS  
PBS     
 
Collagenase A (HUVEC isolation) 
 
Collagenase A 0.01% 
PBS+ Ca2+/Mg2+   
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Before use, FCS gold (fetal calf serum) was partially thawed for 30 min at room 
temperature (RT), followed by total thawing at 37 °C. Afterwards FCS gold was inactivated 
at 56 °C for 30 min and aliquots were stored at -20 °C. FCS in DMEM medium was not 
heat-inactivated. All used cells were routinely tested for mycoplasma contamination using 
the PCR detection kit Venor®GeM (Minerva Biolabs, Berlin, Germany). 
2.2.2 Cell lines 
All cell lines were cultured in an incubator (Heraeus, Hanau, Germany) with constant 
humidity at 37 °C and 5% CO2. Unless otherwise stated, 30 min before use, cell culture 
flasks, Petri dishes multiwell-plates, and µ-slides were coated with collagen G. 
2.2.2.1 HUVECs – human umbilical vein endothelial cells 
Human umbilical cords were kindly provided by Klinikum München Pasing, Wolfart Klinik 
Gräfelfing, Frauenklinik Dr. Krüsmann München, and Rotkreuzklinikum München in 
accordance with the declaration of Helsinki. Until use, umbilical cords were placed in 
PBS+Ca2+/Mg2+ containing penicillin (100 U/ml) and streptomycin (100 µg/ml), and stored 
at 4 °C. Every week HUVECs were freshly prepared by digestion of umbilical veins with 
0.1 g/liter collagenase A. After 45 min incubation at 37 °C, the digestion reaction was 
stopped using stopping medium. The cell suspension of each umbilical cord was 
centrifuged (180 g, 5 min), resuspended in endothelial growth medium, and subsequently 
plated in a 25 cm2 flask. After reaching confluence, cells were trypsinized and plated in a 
75 cm2 flask. For experiments HUVECs were grown until confluence and used only at 
passage #3. HUVECs were used for all assays except for the permeability assays. 
2.2.2.2 HMEC-1 – human dermal microvascular endothelial cells 
Human Microvascular Endothelial Cells (HMEC-1) were kindly provided from the Centers 
for Disease Control and Prevention (CDC, Atlanta, GA, USA) and were used until they 
reached passage #11. The immortalized HMEC-1 cell line was created by transfection of 
human dermal microvascular endothelial cells with a plasmid coding for the transforming 
SV40 large T-antigen. This cell line shows endothelial phenotypic, morphologic, and 
functional characteristics.91, 92 HMECs were solely used in permeability assays. 
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2.2.2.3 Hamster A-Mel-3 amelanotic melanoma cell line 
The spontaneous accrued hamster amelanotic melanoma A-Mel-3 cell line, that was 
cultured at the institute for surgical research of the LMU, was solely used for the 
syngeneic hamster dorsal skinfold experiment (2.11.3). This tumor cell line has intensively 
been characterized93, 94 and is able to build a stable tumor vascularization within 4 days. 
Hamster A-Mel-3 amelanotic melanoma cells were cultured in Roswell Memorial Institute 
Medium (RPMI 1640) containing heat inactivated FCS (PAN Biotech) and were solely 
used at passage #20. 
2.2.2.4 B16-F1 – mouse skin melanoma cell line 
The B16 melanoma arose spontaneously in the skin at the base of the ear of a C57BL/6 
mouse, yielding in two different variants: B16-F1 and B16-F10.95 In this study the less 
metastatic variant B16-F1, which is known to build highly vascularized tumors96, 97 was 
used. B16-F1 cells (No. CRL-6323™) were purchased from ATCC® (American Type 
Culture Collection, Manassas, VA, USA) and cultivated in DMEM containing non heat-
inactivated 10% FCS. B16 F-1 cells were used between passage #21 and #25 in 
syngeneic tumor models (2.11.4 and 2.11.5). 
2.2.3 Passaging 
Confluent HUVECs and HMECs were either sub-cultured 1:3 in 75 cm2 culture flasks or 
were plated for experiments in dishes, multiwell-plates, E-Plates or µ-Slides. For 
passaging, medium was removed and cells were washed twice with PBS. Incubation with 
trypsin/ethylene diamine tetraacetic acid (EDTA) (T/E) followed for 1-2 min at 37 °C. 
Afterwards, cells were gradually detached and the digestion was stopped using stopping 
medium. After centrifugation (180 g, 5 min, 20 °C), the pellet was resuspended in growth 
medium and cells were finally plated. Confluent B16-F1 cells were treated identically but 
were sub-cultured 1:5 or 1:10 in 150 cm2 culture flasks. Cell concentration and viability 
were determined using the ViCELL™ cell viability analyzer (Beckman Coulter, Krefeld, 
Germany).  
2  MATERIALS AND METHODS 24 
2.2.4 Freezing and thawing 
Usually HUVECs were used until passage #3 without intermediate freezing or thawing. 
Before freezing, confluent cells (HMEC-1 and B16-F1) from a 75 cm2 flask were 
trypsinized, centrifuged in stopping medium (180 g, 5 min, 20 °C), and resuspended to  
1 x 106 cells/ml in ice-cold freezing medium. 1.0 ml aliquots were frozen in cryovials at  
-80 °C for 24 h. Afterwards aliquots were moved to liquid nitrogen for long term storage. 
For thawing one cryo-aliquot was rapidly warmed to 37 °C and the content was 
immediately dissolved in pre-warmed growth medium. In order to remove DMSO, cells 
were centrifuged again, resuspended in their suitable growth medium and transferred to a 
75 cm2 (HMEC-1) or a 25 cm2 (B16-F1) culture flask. 
2.3 Western blot analysis 
2.3.1 Sample preparation 
HUVECs were treated as indicated in the respective figure, followed by two washing steps 
on ice with ice-cold PBS. Immediately after washing, cells were lysed in modified RIPA 
lysis buffer for phosphoproteins or in 3x Laemmli sample buffer (MLC2, phospho-MLC2 
and di-phospho MLC2) and were frozen at -80 °C. Afterwards cell samples were gently 
thawed on ice, were scraped off using cell scrapers (TPP, Trasadingen, Switzerland), and 
were transferred to pre-cooled Eppendorf tubes (Peske, Aindling-Arnhofen, Germany). 
After centrifugation (20,160 g, 10 min, 4 °C) one sample (5 µl) of the supernatant was 
diluted 1:10 in H2O to determine the protein concentration by Bradford assay or by 
Bicinchoninic Protein Assay (BCA). The remaining supernatant was mixed with Laemmli 
sample buffer (3x), heated at 95 °C for 5 min and was kept frozen at -20 °C until Western 
blot analysis. To guarantee equal protein loading, each protein sample was adjusted by 
adding 1x Laemmli sample buffer before SDS PAGE.   
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Table 7  Buffers for protein sample preparation 
Lysis buffer for phosphoproteins 
 
3x Laemmli buffer 
Tris/HCl (pH 7.4) 50 mM Tris/HCl (pH 6.8) 187.5 mM 
NaCl 150 mM  SDS (sodium 6% 
Nonidet NP 40 1%  dodecyl sulfate)  
Deoxycholic acid 0.25%  Glycerol 30% 
SDS 0.1%  Bromphenol blue 0.025% 
Na3VO4 0.3 mM  H2O  
NaF 1.0 mM  β-Mercaptoethanol 12.5% 
β-Glycerophosphate 3.0 mM    
Pyrophosphate 10 mM    
H2O     
Freshly added:     
Complete®mini EDTAfree 4.0 mM    
PMSF 1.0 mM    
H2O2 600 µM    
 
2.3.2 Protein quantification 
2.3.2.1 Bradford assay 
The total amount of protein in cell lysates for Western blot analysis was determined as 
described previously.98 Thereby Coomassie Brilliant Blue G250 was used to stain 
proteins. 10 µl samples were incubated with 190 µl Bradford solution (Roti®-Quant 
Bradford Reagent, Carl Roth, Karlsruhe, Germany, 1:5 dilution in H2O) for 5 min at RT 
upon shaking. Afterwards, absorbance was measured photometrically at 592 nm (Tecan 
Sunrise Absorbance reader, TECAN, Crailsheim, Germany). Protein standards were 
obtained by stepwise diluting a 2 mg/ml stock solution of bovine serum albumin (BSA). 
Linear regression was used to determine the protein concentration of each sample.  
2.3.2.2 Bicinchoninic (BCA) protein assay 
The total amount of protein in cell lysates for pull down assays was determined using the 
BCA Protein Assay (BC Assay reagents, Interdim, Montulocon, France) as described 
earlier.99 10 µl samples were incubated with 200 µl BC Assay reagent at 37 °C for 30 min. 
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Afterwards absorbance of the blue complex was measured photometrically at 550 nm. 
Protein standards were achieved as described above (2.3.2.1). 
2.3.3 SDS-PAGE 
After boiling the samples for 5 min at 95 °C, equal amounts of protein were loaded onto a 
SDS-polyacrylamide gel consisting of a separating and a stacking gel. Proteins were 
separated according to Laemmli et al.,100 by discontinuous SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) using the Mini-PROTEAN 3 electrophoresis module (Bio-
Rad, Munich, Germany). To achieve optimal separation of proteins, the concentration of 
acrylamide (Rotiphorese™ Gel 30, Carl Roth GmbH & Co. KG, Karlsruhe, Germany) in 
the separating gel was adjusted to the respective molecular weight. Electrophoresis was 
performed at 100 V for 21 min (protein stacking) and at 200 V for 45 min (protein 
separation). To identify the molecular weight of proteins, samples were compared with a 
pre-stained protein ladder (PageRuler™, Fermentas, St. Leon-Rot, Germany) which was 
additionally load on the SDS gel. 
Table 8  Acrylamide concentration in the separation gel 
Protein Acrylamide conc. 
p38, phospho-p38, MYPT-1, phospho-MYPT-1 10% 
ERK1/2, phospho-ERK1/2, JNK, phospho-JNK 12% 
MLC2, phospho-MLC2, di-phospho-MLC2, HSP27, phopho-
HSP27, RhoA 15% 
Table 9  Acrylamide gels 
Separating gel 10%/12%/15% 
 
Stacking gel 
RotiphoreseTM Gel 30  33.3%/40%/ 
49.7% Rotiphorese
TM
 Gel 30 17% 
Tris (pH 8.8) 375 mM  Tris (pH 6.8) 125 mM 
SDS 0.1%  SDS 0.1% 
TEMED 0.1%  TEMED 0.2% 
APS 0.05%  APS 0.1% 
H2O   H2O  
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Table 10  Electrophoresis buffer 
Electrophoresis buffer 
Tris  4.9 mM 
Glycine 38 mM 
SDS 0.1% 
H2O  
2.3.4 Tank electroblotting 
After protein separation, proteins were transferred to a nitrocellulose membrane (Hybond-
ECL™, Amersham Bioscience, Freiburg, Germany) via tank electroblotting.101 A blotting 
sandwich, which was prepared in a box filled with cold 1x tank buffer, was used for bubble 
free electroblotting. The assembly of the sandwich was as follows: cathode–pad–blotting 
paper–separating gel (SDS-PAGE)–nitrocellulose membrane–blotting paper–pad–anode. 
The membrane was equilibrated for 30 min in 1x tank buffer before starting the tank blot. 
Sandwiches were mounted in the Mini Trans-Blot® system (Bio-Rad, Munich, Germany) 
and the chamber was filled with cold 1x tank buffer. To avoid excessive heat, a cooling 
pack was additionally inserted. Transfers were carried out at 4 °C, 100 V for 90 min. 
Table 11  Tank blotting buffer 
5x Tank buffer 
 
1x Tank buffer 
Tris base 240 mM 5x Tank buffer 20% 
Glycine 195 mM  Methanol 20% 
H2O   H2O  
2.3.5 Protein detection 
2.3.5.1 Control-staining of polyacrylamide gels 
To verify protein loading and homogeneity, polyacrylamide gels were stained after tank 
elektroblotting with Coomassie blue for 15 min. To visualize proteins the excess of 
Coomassie blue was removed using the Coomassie-destaining solution.  
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Table 12  Coomassie staining and de-staining solutions 
Coomassie staining solution 
 
Coomassie de-staining solution 
Coomassie blue 3.0 g Glacial acetic acid 100 ml 
Glacial acetic acid 100 ml  Ethanol 333 ml 
Ethanol 450 ml    
H2O ad 1 l  H2O ad 1 l 
 
2.3.5.2 Protein detection on nitrocellulose membranes 
Prior to the immunological detection of the relevant proteins, unspecific protein binding 
was blocked at RT using either non-fat dry milk powder 5% (Blotto) or BSA 5% for 2 h. 
Afterwards the membranes were incubated overnight at 4 °C with the respective primary 
antibody dissolved either in Blotto or BSA (Table 13). After four washing steps with PBS 
containing 0.1% Tween® 20 (PBS-T), the membrane was incubated with the secondary 
antibody (Table 14) at RT, followed by four washing steps with PBS-T and one washing 
step with PBS. All incubation steps were performed under gentle agitation. To visualize 
the proteins, two different methods were used, depending on the labels of the secondary 
antibodies: enhanced chemiluminescence or infrared imaging. 
2.3.5.2.1 Enhanced chemiluminescence 
Membranes were incubated for 2 h with secondary antibodies conjugated to horseradish 
peroxidase (HRP) (Table 14). For protein detection, luminol (5-amino-2,3-dihydro-1,4-
phtalazinedione) served as substrate. The membrane was either incubated with a 
homemade ECL (enhanced chemiluminescence) solution (2.5 mM luminol, 1 mM p-
coumaric acid, 1 M Tris-Base pH 8.5, 30% H2O2 and dH2O) or with a purchased ECL 
solution (ECL Plus Western Blotting Detection Reagent RPN 2132, GE Healthcare, 
Munich, Germany) for 1 min in the dark. Luminescence was detected by exposure of the 
membrane to an X-ray film (Super RX, Fuji, Düsseldorf, Germany), which was developed 
using the Curix 60 Developing system (Agfa-Gevaert AG, Cologne, Germany) protected 
from light. 
2.3.5.2.2 Infrared imaging 
Secondary antibodies coupled to IR(infrared)Dye™ 800 and Alexa Fluor® 680 with 
emission at 800 and 700 nm, respectively, were used. Membranes were incubated for 1 h 
followed by four washing steps with PBS-T and one washing step with PBS. Afterwards 
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protein bands of interest were detected using the Odyssey imaging system (Li-COR 
Biosciences, Lincoln, NE). Used secondary antibodies are listed in Table 14. 
Table 13  Primary antibodies 
Antigen Source Dilution In Provider 
β-actin (C4)  mouse monocl. 1:1,000 Blotto 5% Millipore 
β-tubulin rabbit polycl. 1:1,000 Blotto 5% Cell Signaling 
HSP27  mouse monocl. 1:500 BSA 5% Cell Signaling 
phos.-HSP27Ser82  rabbit polycl. 1:500 BSA 5% Cell Signaling 
ERK1/2 rabbit polycl. 1:1,000 BSA 5% Cell Signaling 
phos.-ERK1/2T202/Y204 mouse monocl. 1:1,000 BSA 5% Cell Signaling 
JNK rabbit polycl. 1:500 BSA 5% Cell Signaling 
phos.-JNKT183/Y185 rabbit polycl. 1:500 BSA 5% Cell Signaling 
MLC2 (FL-172)  rabbit polycl. 1:500 Blotto 5% Santa Cruz 
phos.-MLC2Ser19  mouse monocl. 1:1,000 Blotto 5% Cell Signaling 
phos.-MLC2T18/S19 rabbit polycl. 1:1,000 BSA 5% Cell Signaling 
MYPT1 (H-130) rabbit polycl. 1:500 Blotto 5% Santa Cruz 
phos.-MYPT1Thr696  rabbit polyc.l 1:500 Blotto 5% Millipore 
p38  rabbit polycl. 1:1,000 BSA 5% Cell Signaling 
phos.-p38T180/Y182  rabbit polycl. 1:1,000 BSA 5% Cell Signaling 
RhoA mouse monocl. 1:666 BSA 3% Thermo Scientific 
Table 14 Secondary antibodies 
Antibody Dilution In Provider 
Goat anti-mouse IgG1 HRP 1:1,000 Blotto 1% Biozol 
Goat anti-rabbit HRP 1:10,000 Blotto 1% Dianova 
Alexa Fluor® 680 goat anti-mouse IgG 1:10,000 Blotto 1% Molecular Probes 
IRDye™ 800W goat anti-rabbit IgG 1:10,000 Blotto 1% LI-COR Biosciences 
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2.4 Active RhoA Pull-Down assay 
HUVECs were grown to confluence in 100 mm dishes and treated with vehicle control or 
PT as indicated. Active RhoA isolation was performed according to the manufacturer´s 
protocol (Active Rho Pull-Down and Detection Kit No. 16116, Thermo Scientific, Rockford, 
IL, USA). An immobilized glutathione, which has been covalently attached to agarose-
resin beats, binds to glutathione-S-transferase (GST)-fusion proteins of the Rhotekin-
bining domain (RBD), which specifically pull down active RhoA out of the whole cell 
lysate. After purification, protein concentrations were determined by the BCA Protein 
Assay (2.3.2.2.), mixed with 2x Laemmli sample buffer (Kit), and stored at -20 °C until 
SDS-PAGE and Western Blot analysis (2.4). After Western blot analysis, quantification 
was carried out using the ImageJ 1.45s software (National Institutes of Health, USA). 
Figure 12 Schematic overview about the functional principle of the RhoA pull-down assay. Adapted 
according to Thermo Scientific (www.piercenet.com).  
2.5 Immunocytochemistry and confocal laser scanning 
microscopy 
Immunofluorescence images of fixed cells were obtained by using a Zeiss LSM 510 
META confocal microscope (Zeiss, Oberkochen, Germany) and 40x or 63x oil immersions 
objectives, respectively. 
2.5.1 F-actin, pp-MLC2, and EC junction staining 
HUVECs were cultured to confluence on 8-well µ-Slides (ibiTreat; IBIDI GmbH, 
Martinsried, Germany) and incubated with PT as indicated. For stainings using inhibitors, 
HUVECs were either pre-treated for 30 min (Y-27632, 10 µM) or for 1 h (SB203580, 20 
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µM or SP600125, 25 µM), followed by 1 h PT treatment. After stimulation cells were 
washed with warm PBS+ (Ca2+/Mg2+), fixed for 10 min with 10% Accustain® 
paraformaldehyde at RT (ppMLC, vinculin and F-actin), or with ice-cold acetone at -20 °C 
for 10 min (VE-cadherin, claudin-5 and F-actin). After three washing steps with PBS, cells 
were permeabilized (only ppMLC, vinculin and F-actin) for 30 min with 0.2% Triton X-100/ 
0.1% Tween® 20 in PBS. Washed cells were incubated for 20 min with 2% BSA in PBS to 
block unspecific binding. Afterwards cells were incubated over night at 4 °C with the 
primary antibody (Table 15). Following three washing steps with PBS, cells were 
incubated for 1 h at RT with the respective AlexaFluor®-labeled secondary antibody, with 
rhodamine-phalloidine for F-actin staining, or with Hoechst 33342 (Bisbenzimide) for 
nuclei staining (Table 16). After three washing steps, cells were embedded in FluorSave™ 
Reagent mounting medium and covered with 8 mm x 8 mm glass coverslips (custom 
made by Helmut Saur Laborbedarf, Reutlingen, Germany). Slides were stored at 4 °C 
protected from light until use. 
2.5.2 Microtubule staining 
HUVECs were cultured as described above, and were treated with PT or CA-4P as 
indicated. To visualize solely polymerized microtubules and to diminish background 
staining, monomeric and dimeric tubulin subunits were removed using the cell extraction 
buffer (CEB; 80 mM PIPES pH 6.9, 1 mM MgCl2, 5 mM EGTA-K and 0.5% TritonX-100). 
After incubation for 30 s, cells were fixed for 10 min by adding glutaraldehyde to final 
0.5%. Redundant glutaraldehyde was removed and quenched for 7 min with 0.1% NaBH4 
in PBS. After washing with PBS, cells were blocked and stained as described in (2.5.1.). 
Table 15 Primary antibodies 
Antigen Source Dilution In Provider 
Claudin-5 rabbit polycl. 1:50 BSA 0.2% Invitrogen 
phos.-MLC2T18/S19 rabbit polycl. 1:400 BSA 2% Cell Signaling 
VE-cadherin (F-8) mouse monocl. 1:400 BSA 0.2% Santa Cruz 
Vinculin (clone 
hVIN-1) 
mouse monocl. 1:100 BSA 2% Sigma-Aldrich 
α-tubulin rabbit polycl. 1:400 BSA 0.2% Abcam 
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Table 16 Secondary antibodies and dyes 
Antibody/dye Dilution In Provider 
Alexa Fluor® 633 goat anti-mouse IgG 1:400 BSA 0.2% Molecular Probes 
Alexa Fluor® 488 goat anti-rabbit IgG 1:400 BSA 0.2% Molecular Probes 
Alexa Fluor® 488 goat anti-mouse IgG 1:400 BSA 0.2% Molecular Probes 
Hoechst 33342 (Bisbenzimide) 1:1000 BSA 0.2% Sigma-Aldrich 
Rhodamine phalloidine 1:400 BSA 0.2% Molecular Probes 
2.6 Permeability assays 
2.6.1 Impedance measurement 
Changes in endothelial permeability were measured by impedance sensing using the 
xCELLigence Real-time-cell-analyzer (RTCA) DP Instrument (Roche, Penzberg, 
Germany), consisting of the RTCA control unit, the RTCA DP station, which was placed in 
a humidified incubator maintained at 37 °C with 5% CO2, and the E-Plate16 (Figure 13). 
The electronic sensors at the bottom of the E-Plate 16 provided a continuous and 
quantitative measurement of cell index (CI) in each well, which represents a 
dimensionless value derived from measured electrical impedance changes. 4 x 104 
HMECs per well were seeded on gold electrodes and grown up to 2.5 days to obtain 
confluency. At CI maximum, normalization was performed and HMECs were treated with 
PT as indicated. Impedance was measured at 25 kHz every 10 s up to 12 h. Quantitative 
analysis was performed at time-point 1 h after PT treatment.  
Figure 13  Principle of impedance sensing using the E-Plate 16. Attachment of cells to the electrode 
(yellow) affect the local ionic environment, thus leading to an increase in impedance. Partially adapted 
according to ACEA Biosciences (www.aceabio.com). 
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2.6.2 Macromolecular permeability assay 
HMECs were grown to confluency on collagen G-coated 12-well Transwell® inserts (0.4 
µm; Corning, New York, NY, USA). Shortly before PT treatment, fluorescein 
isothiocyanate (FITC)-dextran (40 kDa; 1 mg/ml; Sigma-Alrich, Taufkirchen, Germany) 
was used as a tracer and added to the upper compartment of the Transwell® chamber. 
HMECs were treated with PT as indicated. After 30, 60, 120, and 240 min, the amount of 
FITC-dextran in the lower compartment was determined by a SpectraFluorPlus plate 
reader (ex: 485 nm, em: 535 nm; Tecan, Crailsheim, Germany). Mean fluorescence of 
samples from untreated cells at t = 4 h was defined as 1. 
Figure 14  Scheme of a Transwell® insert in combination with a HMEC monolayer. Partially adapted 
according to Genetimes Technology (www.genetimes.hk). 
2.7 Cell viability assays 
2.7.1 CellTiter-Blue® cell viability assay 
Metabolic activity was measured by the CellTiter-Blue® Reagent, which uses resazurin as 
an indicator dye of cell viability. Resazurin (non-fluorescent) is reduced by viable cells into 
resorufin (highly fluorescent). The assay was performed according to the manufacturer´s 
protocol (Promega Corp., Madison, WI, USA). HUVECs were grown to confluency in 96-
well plates and were either simultaneously treated with PT and resazurin (4 h) or were 
pre-treated with PT for 22 h, and then resazurin was added for 4 h. Fluorescence (ex: 560 
nm; em: 590 nm) was detected by a SpectraFluorPlus plate reader, which correlates to 
the number of viable cells.  
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2.7.2 Flow cytometry 
This method was used to determine apoptotic and necrotic cells as well as for cell cycle 
measurement upon treatment with PT. Therefore two different FACS machines, the 
FACSCalibur (apoptosis, cell cycle) and the FACSCanto II (necrosis; both Becton 
Dickinson, Heidelberg, Germany) were used. The necessary FACS buffers were either 
self-made (FACSCalibur, Table 17) or were purchased from BD Biosciences (FACSCanto 
II, BD FACSFlow™ No. 342003). 
Table 17 FACS buffer for FACSCalibur 
Sheat fluid pH 7.4 
 
NaCl 8.1 g 
KH2PO4 0.3 g  
Na2HPO4 2.4 g  
KCl 0.3 g  
Na2EDTA 0.4 g  
LiCl 0.4 g  
NaN3 10 mM  
H2O ad 1 l  
 
2.7.2.1 Quantification of apoptotic cell death 
Quantification of apoptosis was carried out as described by Nicoletti et al.102 by counting 
the nuclei with subdiploid DNA content after staining with propidium iodide (PI). Confluent 
HUVECs, grown in 24-well plates, were either left untreated (control) or were pretreated 
with PT as indicated. After treatment, the supernatant of each well was collected and cells 
were washed two times with PBS. Afterwards, cells were trypsinized with T/E, 
resuspended in the supernatant and centrifuged (10 min, 4 °C, 600 g). Following two 
washing steps with PBS and subsequent centrifugation (10 min, 4 °C, 600 g), cells were 
incubated in a hypotonic fluorochrome solution (HFS) overnight. Cells were analyzed by 
flow cytometry (FACSCalibur), whereby events left of the G0/G1 peak in the histogram 
were considered as apoptotic cells.   
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Table 18 HFS solution 
HFS solution 
 
Sodium citrate 0.1% 
Triton X-100 0.1%  
Propidium iodide 50 µg/ml  
PBS ad 1 ml  
2.7.2.2 Cell cycle analysis 
After incubation in HFS solution (see above) HUVECs were measured by using the 
fluorescence channel 2 (FL2, em: 585) in the logarithmic mode. Since PI intercalates in 
the DNA and PI-fluorescence depends on the status of cellular chromatin, the different cell 
cycle phases can be distinguished. Most cells are in the G0/G1 cell cycle phase with 2n 
chromosome set (= diploid), lacking the sister chromatids. Cells in the G2/M phase are in 
the process of cell division, meaning that these cells have a 2n chromosome set, but 
furthermore the sister chromatides as duplicates (= tetraploid). The additional sister 
chromatide allows the differentiation of the G2/M-phase to G0/G1-phase, which results in 
a higher fluorescence peak due to the increased amount of propidium-iodide intercalation. 
The S-phase is the synthesis phase. In this phase the chromatids duplicated and the 
fluorescence peak is located between the fluorescence peaks of G0/G1 and G2/M-phase. 
Using the Flow cytometry analysis software FlowJo 7.6, regions for each fluorescence 
peak according to their chromatin states (percentages of cells in the single cell cycle 
states) were measured and set into relation of the total cell number. 
2.7.2.3 Quantification of necrotic cell death 
To assess the number of cells undergoing necrosis or late apoptosis, PI-staining was 
performed. Confluent HUVECs grown in 24-well plates were pretreated with PT as 
indicated. After treatment, cells were incubated with 10 µg/ml PI at 37 °C for 30 min. One 
control well was incubated with 0.01% Triton and served as positive control. The 
supernatant of each well was collected and centrifuged for 10 min at 600 g. In parallel, the 
remaining cells were washed two times with PBS and trypsinized with T/E. After 
centrifugation the supernatant was removed and trypsinized cells (in stopping medium) 
were added. Following centrifugation for 10 min at 600 g, cells were analyzed by flow 
cytometry (FACSCanto II). 
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2.7.3 Monitoring of morphological changes 
HUVECs were cultured to confluence in 24-well plates and were treated with PT as 
indicated. After 1 h and 24 h images were taken using a Canon EOS 450 D digital camera 
and a Zeiss-Axiovert-25 microscope (10x objective; Zeiss, Oberkochen, Germany). 
Afterwards HUVECs were washed twice with PBS and fresh ECGM was added. 24 h later 
images of the same wells were taken again.  
2.8 VE-cadherin quantification via FACS analysis 
The amount of extracellular VE-cadherin upon PT treatment was determined by FACS 
analysis as described in (2.7.2.). Confluent HUVECs were treated as indicated, fixed for 
10 minutes in 4% methanol-free formaldehyde (Polyscience, Warrington, PA, USA), 
centrifuged (10 min, 219 g, RT), washed with PBS and centrifuged again. After incubation 
with anti-VE-cadherin-FITC antibody (1 h, RT) extracellular VE-cadherin was detected by 
flow cytometry (FACSCanto II). 
Table 19 Primary antibody 
Antigen Source Dilution Provider 
VE-cadherin (CD144)-FITC rabbit polycl. 1:14 in PBS Acris Antibodies 
2.9 Endothelial tube disruption assays 
2.9.1 Tube disruption (in vitro) 
µ-slide angiogenesis (Ibidi GmbH) were coated with cold Matrigel® by adding 10 µl to the 
lower compartment of the slide. After setting (37 °C, 30 min), 1.2 x 104 HUVECs in ECGM 
were seeded onto the Matrigel®, and grew until thin endothelial tubes become visible 
(approx. 16 h). Established tubes were treated with PT as indicated and images of each 
well were taken using the TILLvisION 4.0.1.2 (TILL Photonics, Gräfelfing, Germany) 
system with an Axiovert 200 microscope (10x objective; Zeiss, Jena, Germany). The 
images were analyzed with the tube formation module of WIMASIS Image Analysis 
(Munich, Germany), which identifies cellular tubes on a variety of parameters (e.g. 
depending on brightness and contrast differences, length and width of structure) by an 
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automated mathematic algorithm. Drug effects were assessed at time point 6 h after 
treatment, analyzing total tube length, total tubes, and total branching points.  
2.9.2 Mouse aortic ring assay (ex vivo) 
Aortae from adult female C57BL/6 mice were prepared in PBS, cleaned from fat tissue, 
cut and embedded into Matrigel®. After 30 min incubation at 37 °C, aortic rings were 
covered with ECGM. Once endothelial cell sprouting occurred (after 10 d), aortic rings 
were treated with PT as indicated and images were taken using a Zeiss Axiovert 200 
inverted light microscope (10x objective; Zeiss) connected to an IMAGO-QE camera and 
the appending software TILLvisION 4.0.1.2. (TILL Photonics). One representative image 
of 14 aortic rings prepared from six different mice aortae (animal #1 and #6: 3 rings, each; 
animal #2: 4 rings; animal #3 and #5: 1 ring, each; animal #4: 2 rings) is shown. 
Quantification was carried out using the ImageJ 1.45s software. 
2.10 Cytosolic calcium imaging 
Intracellular calcium measurement was carried out using a static tempered system. The 
fluorescent dye Fura-2103 was used to detect ratiometrically changes of cytosolic calcium 
concentrations. Upon calcium binding, the excitation maximum of Fura-2 is shifted from 
380 nm to 340 nm, whereas the emission wavelength of 510 nm remains unchanged. This 
results in a direct correlation between the emission ratio of 340/380 and the amount of 
cytosolic calcium. For measurements, a membrane permeable derivative named Fura-2-
acetoxymethyl ester (Fura-2-AM, Biotrend, Cologne, Germany), which is cleaved to Fura-
2 by cellular esterases after passing the membrane, was used. HUVECs were grown to 
confluency on 8-well µ-slides (Ibidi GmbH) and incubated for 30 min at 37 °C with 2 µM 
Fura-2-AM in HEPES buffer (Table 20). Afterwards cells were washed twice (HEPES) and 
treated with PT as indicated. Fluorescence measurements were performed at 37 °C, 80% 
humidity and 5,2% CO2 under light protection. For each sample, a total period of 55 min 
with images being acquired every 5 s was analyzed with the TILLvisION Software 4.0.1.2 
(TILL Photonics). Each data point of the different graphs was calculated from a randomly 
chosen rectangle containing at least 25 adjacent cells, of which mean values are 
expressed. To obtain a positive calcium signal and to confirm that cells are still alive after 
PT treatment, 10 µM histamine was added at time point 45 min and data were recorded 
for further 10 min. For data acquisition, a Zeiss Axiovert 200 M (40x objective; Zeiss) 
microscope, a polychromator illumination system (VisiChrome High Speed, Xenon lamp, 
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Visitron Systems, Puchheim, Germany) and a thermoelectric-cooled CCD camera 
(Photometrics Coolsnap HQ, Visitron Systems) were utilized.  
Table 20  HEPES buffer for Ca2+ measurement 
HEPES buffer (pH 7.4) 
CaCl2 2.5 mM 
NaCl 125 mM 
NaH2PO4 1.3 mM 
MgCl2 1.5 mM 
KCl 3 mM 
HEPES 10 mM 
Glucose 10 mM 
H2O  
2.11 In vivo experiments 
2.11.1 Animals 
All animal care and experimental procedures were in accordance with the local animal 
protection legislation (Government of Upper Bavaria). Experiments were carried out using 
male Syrian golden hamsters (6-8 weeks old, 60 ± 5 g body weight) and female C57BL/6 
mice (6-12 weeks old, 20 ± 5 g body weight) both purchased from Charles River 
(Sulzbach, Germany). The animals were maintained in a specific pathogen-free 
environment, with food and water provided ad libitum. 
2.11.2 Determining the maximum tolerated dose (MTD) of PT 
Different concentrations of PT (1, 10, 30 and 50 mg/kg in PBS) were injected 
intravenously (IV) into the tail vein of female C57BL/6 mice. Weight was measured every 
day up to 8 days.  
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2.11.3 Hamster dorsal skinfold chamber measurement 
This experiment was carried out in cooperation with Donata Gellrich from the Walter-
Brendel-Center for Experimental Medicine (LMU Munich).  
To perform quantitative fluorescence analysis of tumor microcirculation in vivo, a dorsal 
skinfold chamber consisting of two titanium plates was surgically implanted into the dorsal 
skin as described earlier.93, 94, 104 24 h after microsurgery, the chambers were proven to 
fulfill the criteria of an intact microcirculation and if they passed, a dense tumor cell 
suspension (2 µl, ∼2 x 105 cells) of the hamster A-Mel-3 amelanotic melanoma was 
inoculated onto the striated skin muscle layer. For intravenous (IV) injection of fluorescent 
tracers and PT, permanently indwelling fine polyethylene catheters (PE10, inner diameter 
0.28 mm, Portex, Hythe, UK) were additionally implanted into the right jugular vein, seven 
days upon tumor cell inoculation. All surgical procedures were performed under 
intraperitoneal anesthesia with ketamine (100 mg/kg b.w., Ketavet®; Parke-Davis, Berlin, 
Germany) and xylazine (10mg/kg b.w., Rompun®; Bayer, Leverkusen, Germany), and 
animals were kept warm using common heating plates. Ten days after tumor cell 
implantation, intravital microscopy was performed. The awake animals were immobilized 
in a Perspex tube on a purpose build stage (Effenberger, Munich, Germany) under a 
modified Zeiss microscope (Axiotech vario; Zeiss, Oberkochen, Germany). To visualize 
tumor microcirculation, fluorescein isothiocyanate (FITC-)labeled dextran (MW 500 kDa; 
0.05-0.1 ml of a 5% solution in 0.9% NaCl; Sigma, Deisenhofen, Germany) was injected 
IV prior to PT injection, and determination of the baseline followed. A total of 5 regions of 
interest (ROIs) per animal were randomly selected and FITC-labeled plasma was 
selectively observed by epi-illumination with a 100 W mercury vapour lamp and specific 
fluorescence filter sets (excitation 450-490 nm, emission ≥ 515 nm). Directly upon FITC 
injection, 10 mg/kg PT or vehicle control (5% DMSO) was administered IV and data were 
recorded for 30, 60 and 120 min. Three microcirculation parameters in each of the five 
ROIs per animal were quantified: capillary red blood cell velocity (vRBC in mm/s), capillary 
diameter (D in µm) and functional vessel density (FVD in 1/mm) defined as the total length 
of perfused capillaries per area. The images acquired by a CCD camera (Sony XC-77CE; 
Sony, Cologne, Germany) were recorded on digital video tape (Sony DVCAM DSV 45P; 
Sony, Cologne, Germany) and quantitative assessment of microcirculatory parameters 
and tumor growth was performed off-line using the Cap Image software (Zeintl, 
Heidelberg, Germany) as described in detail by Zeintl105 and Klyscz.106 Vessel diameters 
and red blood cell velocity were measured in at least 3 vessels per ROI in order to 
improve the steadiness of data analysis.  
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Figure 15  Images of dorsal skinfold chamber preparation. Window chamber image (right) kindly 
provided by Donata Gellrich. 
2.11.4 B16-F1 mouse melanoma tumor model (single dose) 
C57BL/6 mice were injected subcutaneously (s.c.) into the left hind limb with 100 µl of a 
1x106 B16-F1 mouse melanoma cell suspension in PBS, using a 0.40 x 20 mm needle 
and a 0.01 – 1 ml Inject-F Tuberculin Luer solo syringe (B. Braun, Melsungen, Germany). 
The mice were entered into experiments once tumors reached a size of approximately 
650 mm3 (assessed by π/6 x width x height x length). PT was prepared in PBS and 
injected IV into the tail vein at a dose of 10 mg/kg, using a 0.30 x 12 mm needle (B. 
Braun). Control mice received IV 5% DMSO in PBS. 24 h after treatment, 10 mg/kg of the 
perfusion marker Hoechst 33342 (Sigma-Aldrich) was injected IV 1 min before tumor 
removal. After tumor preparation, one half of the tumor was flash frozen in frozen section 
medium (Thermo Fisher Scientific, Bonn, Germany) (2.11.4.1), and the second tumor-half 
was fixed in 4% (4 days) and 1% (1 week) paraformaldehyde (2.11.4.2).  
2.11.4.1 Quantification of Hoechst 33342 perfusion and vessel density 
10 µm cryo-sections were prepared using a microtome cryostate HM 500 (Microm, 
Walldorf, Germany) to visualize Hoechst 33342 perfusion and vessel density (CD31). 
Upon air-drying (15 min, RT) tumor-sections were washed twice in PBS, were fixed for 10 
min in 4% paraformaldehyde and were blocked with 2% BSA containing 0.5% Triton X-
100 for 30 min. Afterwards tumor sections were incubated with an rat anti-mouse CD31 
monoclonal antibody (BD PharmingenTM, Heidelberg, Germany) 1:100, over night at 4 °C. 
Secondary antibody Alexa Fluor® 546 goat anti-rat 1:400 for 2 h (Invitrogen, Karlsruhe, 
Germany) was used for detection. Hoechst 33342 and CD31 staining were visualized 
using a Zeiss LSM 510 Meta confocal microscope and a 40x magnification. Overall 
thirteen random fields at the tumor periphery as well as in the tumor center of two sections 
per tumor were analyzed. For quantification, Hoechst 33342 fluorescence intensity was 
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determined using ImageJ 1.44p software according to Grosios et al107 and vessel density 
was quantified by counting CD31 pos. vessel-like structures. 
2.11.4.2 Haematoxylin and eosin staining (H&E) 
After paraformaldehyde fixation, dehydration and paraffin embedding, 5 µm tumor 
sections of PT (10 mg/kg, IV) and DMSO (5%, IV) pre-treated mice were cut by a Leica 
RM2265 rotary microtome (Leica Biosystems, Wetzlar, Germany) and stained using 
haematoxylin and eosin according to the manufacturer´s protokoll (H&E; Sigma Aldrich, 
Steinheim, Germany). Afterwards tumor histology of two different sections of DMSO- and 
PT-treated mice was analyzed under 4x magnification using the Olympus CellSens Entry 
software in combination with an Olympus DP25 camera, connected to an Olympus Bx41 
stereomicroscope (Olympus, Munich, Germany). The area of necrotic regions was 
determined by ImageJ 1.44p software. 
2.11.5 B16-F1 mouse melanoma tumor model (multiple doses) 
The preparation of the repeated treatment approach was performed as described under 
2.11.4, but started once tumors reached a size of about 90 mm3. PT (10 mg/kg) or DMSO 
(5% in PBS) was injected IV every third day up to 3 times. Tumor size was determined 
every day (assessed by π/6 x width x height x length), and daily measurement of mouse 
weight served as health control. 
2.12 Statistical analysis 
The number of independently performed experiments (n) is stated in the respective figure 
legend. If HUVECs were used, a different cell preparation from different donors was 
performed each time. Bar graph data are expressed as means ± S.E.M. Statistical 
analysis was performed with Prism software (version 5.04; GraphPad Software, San 
Diego, CA, USA). For comparison of two groups an unpaired t-test was performed. Three 
or more groups were compared by one-way analysis of variance (ANOVA) followed by a 
Newman-Keuls multiple comparison post-test. Statistical significance is assumed if  
p ≥ 0.05. 
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3.1 PT induces typical hallmarks of vascular disruption in 
ECs in vitro  
Previous work already demonstrated that PT shows an anti-angiogenic potential in 
proliferating EC in vitro as well as in vivo16 and is even able to inhibit cancer cell migration 
and survival.15 In the present study we aimed to investigate the potential of PT to induce 
typical hallmarks of vascular disruption. Since VDAs are described in literature to induce 
first significant effects within a few hours after treatment,70-72 we designed our experiments 
by using short incubation times with PT (1-6 h). We first focused on PT induced EC effects 
in vitro and simulated an intact vasculature by using confluent endothelial monolayers. 
3.1.1 PT induces the depolymerization of microtubules  
Eirich et al.108 and Rath et al.16 already demonstrated that PT is able to directly target 
microtubules and to induce their depolymerization in proliferating EC. To investigate if PT 
is able to destroy microtubules in our system (confluent ECs), we performed 
immunofluorescence stainings of polymerized microtubules. Untreated HUVECs showed 
intact, polymerized, filamentous microtubules, whereas PT treatment for 1 h with 10, 30, 
100 and 300 nM induced a concentration-dependent microtubule depolymerization (Figure 
16 upper panel). Combretastatin A-4-phosphate (CA-4P), the lead VDA, showed 
depolymerization in a similar extent under the same conditions (Figure 16 lower panel), 
suggesting that PT is of comparable potency regarding its tubulin-destroying action. 
Figure 16  PT leads within 1 h to a concetration-dependent depolymerization of microtubules. 
Confluent HUVECs were either left untreated (control) or were pre-treated for 1 h with 10, 30, 100, and 300 
nM PT or CA-4P. After washing out of tubulin-monomers and -dimers, remaining polymerized microtubules 
were stained with an anti-α-tubulin antibody (green) and nuclei were visualized by Hoechst 33342 (blue). One 
representative experiment out of four is shown. Scale bar represents 50 µm. 
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3.1.2 PT triggers actin stress fiber formation, disrupts EC 
junctions, and induces reorganization of focal adhesions 
Besides alterations of the microtubule cytoskeleton, PT caused morphological changes of 
HUVECs and induced intracellular gap formation, which is indicative for actin cytoskeleton 
changes and the disassembly of cell-cell contacts. We treated confluent HUVECs with 30 
and 300 nM PT (10 and 100 nM data not shown) and analyzed (via immunofluorescence 
stainings) F-actin, adherens junctions (VE-cadherin), tight junctions (claudin-5) and focal 
adhesions (vinculin). 1 h incubation with 300 nM PT led to the formation of prominent actin 
stress fibers across the cell body and induced disruption of adherens and tight junctions, 
thereby forming huge intracellular openings (Figure 17, arrow heads, lowest panel). In 
contrast, control cells showed the typical appearance of junctions at the cell margin 
(Figure 17 upper panel). Focal adhesions were not disassembled but showed a strong 
redistribution into pronounced clustered structures. 
Figure 17  PT treatment induces F-actin formation, disrupts cell-cell connections and reorganizes 
focal adhesions within 1 h. HUVECs were treated with vehicle control, 30 or 300 nM PT for 1 h and were 
stained for actin with rhodamine phalloidine (red), for adherens and tight junctions with antibodies against VE-
cadherin (left green) and claudin-5 (white), and for focal adhesions using an anti-vinculin antibody (right 
green). Arrowheads indicate intracellular openings. Images were taken by the confocal laser scanning 
microscope with a 40x magnification. One representative experiment out of three is shown. Scale bars 
represent 50 µm (for F-actin, VE-cadherin and claudin-5) and 20 µm (for vinculin).  
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3.1.3 PT rapidly induces endothelial barrier breakdown 
Cellular changes, as described in 3.1.1 and 3.1.2 are in general accompanied by an 
increase in endothelial permeability.109 To prove if PT has any influence on this parameter, 
we performed two different permeability assays. In addition, we quantified the amount of 
extracellular VE-cadherin since it is known to play an important role in regulating 
endothelial barrier function.110  
3.1.3.1 Impedance sensing 
First, we measured impedance of confluent HMECs grown on gold-electrodes (Figure 18). 
We observed a time- and concentration-dependent decrease in electrical impedance (i.e. 
increase in permeability) that reaches the minimum (50%) within 1.5 h upon treatment 
with 100 nM or (40%) within 1 h upon 300 nM PT (Figure 18 A). Quantification of all tested 
concentrations at time point 1 h resulted in an IC50 value of 71 nM (Figure 18 B).  
Figure 18  PT decreases electrical impedance. A: HMECs were seeded on gold electrodes, grown to 
confluence and treated with 10, 30, 100 and 300 nM PT. The vertical black line represents the time point of 
normalization. Impedance was measured every 10 s up to 12 h. One representative graph out of four is 
shown. B: Quantitative analysis of impedance sensing was performed at time point 1 h after treatment. Data is 
expressed as normalized cell index, a dimensionless parameter derived from the measured impedance 
changes (PT mean ± SEM, n = 4). 
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3.1.3.2 Macromolecular permeability  
In a second approach performed with HMECs, we measured PT-induced permeability to 
macromolecules, by using FITC-labeled dextran (40 kDa) as a tracer. After collecting the 
supernatant of the lower compartment, we obtained a time- and concentration-dependent 
increase in transendothelial permeation of dextran (i.e. increase in permeability), whereby 
100 and 300 nM PT led to a significant increase in permeability within 4 h compared 
control cells (Figure 19 A,B). 
Figure 19  PT treatment increases permeability to macromolecules. A: HMECs were grown to 
confluence on Transwell™ inserts and were treated with vehicle control (●), 30 nM PT (▲), 100 nM PT (▼) 
and 300 nM PT (♦). FITC-labeled dextran (40 kDa) was used as a tracer and added to the upper compartment 
of the chamber. After 30, 60, 120 and 240 min the amount of FITC-dextran in the lower compartment of the 
chamber was determined. B: Quantitative analysis was performed at time point 4 h. Control values were set 
as 1. *P ≤ 0.05 versus control, n = 4. 
 
3.1.3.3 PT reduces extracellular VE-cadherin expression 
From literature it is known that especially adherens junctions (composed of vascular 
endothelial cadherin, VE-cadherin) are one of the major components in regulating the 
endothelial barrier function53. Several signal molecules (e.g. Rho, Ca2+, and Src) affect 
VE-cadherin either by phosphorylation and internalization or by its organization and 
expression at the cell surface.110 To assess whether PT treatment influences the 
expression pattern of VE-cadherin, we determined the extracellular amount of VE-
cadherin by FACS analysis. Upon 2 h treatment with 30, 100 and 300 nM PT we observed 
a concentration-dependent decrease of VE-cadherin of about 80% and 300 nM PT (Figure 
20).   
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Figure 20  PT mediates hyperpermeability via reduced extracellular VE-cadherin expression. 
Confluent HUVECs were treated for 2 h with 30, 100 and 300 nM PT. After staining with an anti-VE-cadherin-
FITC antibody, cells were analyzed by flow cytometry. Quantitative analysis was performed at time point 2 h. 
Data are expressed as mean ± S.E.M. (n=4). *P ≤ 0.05 versus control.  
 
Based on this data, we suggest that the PT-mediated hyperpermeability might be a result 
of a reduced VE-cadherin expression at the cell surface, as well as an increased 
actinomyosin contraction (indicated by actin stress fibers) that causes cell retraction and 
disruption of the VE-cadherin complex (see 3.1.2).  
 
3.1.4 PT disrupts established endothelial tubes 
Since the main hallmark of microtubule-targeting VDAs is the selective disruption of 
established tumor blood vessels, we aimed to investigate if PT is able to destroy pre-
existing endothelial tubes in vitro and ex vivo.  
3.1.4.1 PT disrupts endothelial tubes in vitro 
HUVECs were seeded on Matrigel™ and were allowed to form endothelial tubes for 16 h. 
Tubes were then treated with vehicle control, 10, 30, 100, or 300 nM PT (10 and 300 nM 
are not shown). Images were taken before (0 h) as well as after 3 h and 6 h PT treatment 
(Figure 21 A). We observed a concentration-dependent disruption of PT-treated tubes 
starting at 1.5 h after PT addition (not shown), leading to almost complete disruption within 
6 h and 100 nM PT (indicated by arrowheads). We furthermore evaluated and quantified 
the total tube length, the total amount of tubes as well as the total branching points. After 
6 h, all parameters of PT-treated tubes were significantly reduced compared to control 
tubes (Figure 21 B-D).  
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Figure 21  PT disrupts established endothelial tubes in vitro. A: HUVECs were seeded on Matrigel™. 
After 16 h thin endothelial tubes were formed and treated with PT (vehicle control, 30 and 300 nM). Phase 
contrast images before (0 h) and after 6 h treatment were taken. Original magnification: 10x for all panels.  
B-D: Tube disruption was quantified by the WIMASIS module for tube formation at time point 6 h after PT 
treatment. Total tube length (B), total number of tubes (C) and total number of branching points (D) were 
chosen for analysis. Control values were set as 100%. *P ≤ 0.05 versus control, n = 6.  
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3.1.4.2 PT disrupts endothelial sprouts ex vivo 
To confirm our observations and to provide a better relation to the in vivo situation, we 
additionally performed an ex vivo aortic ring assay. Aortic rings prepared from mouse 
aortae were embedded into Matrigel™. Once endothelial sprouts occurred (after 10 d) we 
treated them with 300 nM PT and took images after 3 h and 6 h (Figure 22 A). In 
accordance to the in vitro approach, ex vivo grown aortic sprouts were disrupted within 6 h 
after PT treatment (Figure 22 A indicated by the arrowheads). Quantification of the total 
sprout area confirmed our observations and resulted in a significant disruption already 
after 3 h (Figure 22 B). 
Figure 22  PT disrupts established endothelial sprouts ex vivo. A: Aortic rings were prepared and 
placed into Matrigel™. Once endothelial sprouts were established, they were treated with 300 nM PT. Phase 
contrast images before (0 h) as well as after 3 h and after 6 h treatment were taken. Arrowheads indicate 
disrupted sprouts. One representative experiment out of fourteen is shown. Original magnification: 10x (for all 
panels). B: Quantification was performed using ImageJ 1.45s software. Normalized data (0 h) are expressed 
as mean ± S.E.M. *P ≤ 0.05 versus control (n = 14).  
 
This result demonstrates that PT is able to disrupt established endothelial tubes in vitro 
and ex vivo. 
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3.1.5 PT treatment is not cytotoxic for ECs 
3.1.5.1 Metabolic activity 
To prove that the observed cellular changes, induced by PT, are not of cytotoxic nature, 
we measured metabolic activity using the CellTiter-Blue® reagens resazurin. HUVECs 
were either simultaneously treated with 10, 30, 100 and 300 nM PT plus resazurin (Figure 
23 A) or were pre-treated for 22 h with PT, followed by addition of resazurin for 4 h (Figure 
23 B). Metabolic activity was determined by fluorescence measurement of the resazurin 
metabolite resorufin. PT treatment for 4 h resulted in only a marginal decrease in 
metabolic activity. Even after 26 h of treatment, only a minimal decrease of about 20% 
was observed.  
Figure 23 Short-term treatment with PT did not change metabolic activity and only marginally 
decresaes it upon 26 h PT treatment. A, B: Metabolic activity was measured by the CellTiter-Blue® assay. 
Confluent HUVECs were either simultaneously treated with 10, 30, 100 and 300 nM PT plus resazurin for 4 h 
(A) or were pre-treated for 22 h with PT, followed by addition of resazurin for 4 h (B). Metabolic activity was 
determined by fluorescence measurement of the resazurin metabolite resorufin. Control values were set as 
100%. *P ≤ 0.05 versus control, n=4 (A), n=6 (B). 
 
3.1.5.2 Quantification of apoptotic and necrotic cells 
By FACS analysis we determined the number of apoptotic cells via counting the amount of 
subdiploid DNA content (Figure 24 A) and necrotic cells via propidium iodide staining 
(Figure 24 B). In addition, we also measured the cell cycle (Figure 24 C). After treatment 
with 10, 30, 100 and 300 nM PT for 24 h we observed, compared to control cells, a 
concentration-dependent increase of about 10% in apoptotic cells (Figure 24 A) and an 
increase of about 15% in dead cells (Figure 24 B). We could not detect any G2/M arrest 
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(Figure 24 C), which plays an important role in the onset of apoptosis-mediated cell death. 
To assess the amount of induced cell death, we used 0.01% Triton (T) as positive control. 
An increase of about 60% compared to control cells (Figure 24 B) was detected. This 
result indicates that PT only marginally induces apoptosis and necrosis, which is far away 
from typical substances that trigger cell death. 
Figure 24  PT only marginally induced cytotoxicity after 24 h. A-C: The number of apoptotic (A), and 
necrotic (B) cells as well as cell-cycle phases (C) were determined using confluent HUVECs, which were 
either pre-treated with vehicle control or with 10, 30, 100 and 300 nM PT for 24 h. After permeabilization (A 
and C), cells were stained with propidium iodide (PI) and analyzed by flow cytometry. 0.01% Triton (T) served 
as positive control (only B). Quantification was performed at time point 24 h. *P ≤ 0.05 versus control, n=3 (A-
C). 
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3.1.5.3 Recovery after withdrawal of PT 
To confirm our data (3.1.5.1 and 3.1.5.2) and to demonstrate that the applied PT 
concentration is not toxic to endothelial cells, we treated an intact confluent HUVEC 
monolayer with 10, 30, 100 and 300 nM PT (10 and 100 nM data not shown) and took 
pictures after 1 h and 24 h (Figure 25 A,B upper panel). Incubation with 30 nM for 1 h 
resulted in no obvious cellular changes, however, after 24 h treatment cell retraction was 
visible (Figure 25 A). In contrast, already after 1 h incubation with 300 nM PT (Figure 25 
B) we observed that cells retract and intracellular openings occur, which were still evident 
after 24 h. Removal of PT and addition of fresh medium for 24 h resulted in a complete 
restoration of the HUVEC monolayer, and no difference between 1 h or 24 h PT-treated 
cells was visible. A few dead cells could be observed, indicating that a small number of 
cells underwent apoptosis or necrosis. 
Figure 25  PT-induced cellular effects are reversible. A,B: Confluent HUVECs were treated with 30 nM 
PT (A) or 300 nM PT (B) for 1 h or 24 h (upper row). After removal of PT, cells were washed twice and fresh 
growth medium (ECGM) was added. After 24 h incubation without PT (lower panel) the same well was 
photographed using brightfield microscopy. One representative experiment out of three is shown. Original 
magnification: 10x (for all panels). 
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In summary, we could show that PT exhibits typical features of a vascular disrupting agent 
in ECs in vitro. 
1. PT binds to microtubules and induces their depolymerization  
2. PT leads to an enormous actin stress fiber formation and EC junction disruption  
3. PT strongly increases endothelial permeability 
4. PT destroys established endothelial tubes  
PT did neither considerably influence the metabolic activity of HUVECs, nor induce short 
time apoptosis and cell death. After withdrawal of PT, HUVECs were able to fully rebuild 
their normal morphology, indicating that PT treatment is not cytotoxic. 
 
 
3.2 PT-induced signaling cascades leading to actin 
stress fiber formation and hyperpermeability 
Since PT treatment provokes prominent alterations of the actin cytoskeleton, leading to 
weak cell-cell connections and to endothelial hyperpermeability, we next focused on the 
possible underlying signaling cascades. In literature there are several pathways described 
that impair endothelial barrier function, however, in the context of vascular disruption, only 
two, the RhoA/ROCK/MLC and the p38 MAPK pathways have been described so far to 
play important roles.80, 111 We therefore proved whether these pathways are also involved 
in our system. Additionally, we investigated the influence of intracellular calcium [Ca2+]i 
since it is well known that [Ca2+]i is an important upstream regulator of PKC, Src, Rho and 
MLCK, which in turn promote actinomyosin contraction, junction disruption and endothelial 
hyperpermeability.112  
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3.2.1 Involvement of the RhoA/ROCK/MLC pathway 
3.2.1.1 RhoA 
We performed an active RhoA pull down assay and collected GTP-bound RhoA after 15, 
30, and 60 minutes of 300 nM PT pre-treatment. The amount of active RhoA was 
analyzed by Western blotting (Figure 26 A). We observed an induction of active RhoA 
within 30 min, which significantly increased by about 100% after 1 h PT treatment (Figure 
26 B). The supernatant, which contains inactive GDP-bound RhoA, served as control. 
Figure 26  PT treatment activates RhoA GTPase within 30 min. A: Confluent HUVECs were either pre-
treated with vehicle control (Co) or with 300 nM PT for 15, 30 and 60 min. Active RhoA isolation was 
performed as described in the materials and methods section. One representative experiment out of four is 
shown. B: Quantitative evaluation was performed by ImageJ 1.45s. Data are expressed as mean ± S.E.M. *P 
≤ 0.05 vs. control (n = 4). 
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3.2.1.2 MLC2 
To investigate whether known downstream targets of RhoA were activated, we first 
focused on myosin light chain (MLC). Due to the fact that active RhoA was detectable 
within 1 h treatment, we used this time point for immunocytochemistry experiments. 
HUVECs were pre-treated with 300 nM PT and stained for F-actin with rhodamine 
phalloidine and for MLC with an anti-diphospho MLC(Thr18/Ser19) antibody (Figure 27 A). 
Control cells showed F-actin in peripheral bands along the cell margin and a weak, basal 
activation of MLC(Thr18/Ser19). In contrast, PT-treated HUVECs exhibited stress fiber 
formation and MLC(Thr18/Ser19) activation, which could additionally be confirmed by 
Western blot analysis, by which we observed a clear induction of MLC(Ser19) and 
MLC(Thr18/Ser19) within 30 minutes of PT treatment (Figure 27 B). 
Figure 27  PT treatment activates MLC(Ser19) and MLC(Thr18/Ser19) within 30 min. A: 
Immunocytochemistry and confocal microscopy of di-(Thr18/Ser19) phosphorylated MLC2 upon treatment 
with 300 nM PT for 1 h. One representative experiment out of three is shown. Scale bar represents 50 µm. B: 
Activation of mono(Ser19)- and di(Thr18/ser19)-phosphorylated MLC2 was analyzed by Western blotting. 
Confluent HUVECs were either pre-treated with vehicle control (Co) for 120 min or 5, 15, 30, 60 and 120 min 
with 300 nM. One representative blot out of four is shown. 
 
3.2.1.3 MLCP and MLCK 
The observed increase in MLC phosphorylation could be mediated through inactivation of 
myosin light chain phosphatase (MLCP) by phosphorylation of the catalytic domain, called 
MYPT1, or by activation of the myosin light chain kinase (MLCK). By Western blot 
analysis we could show that PT treatment did neither change the phosphorylation status 
of MYPT1 (Figure 28 A) nor alter MLC phosphorylation when combined with the MLCK 
inhibitor ML-7 (Figure 28 B). This indicates that neither MLCP nor MLCK are involved in 
PT-induced signaling.  
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Figure 28  MLCP and MLCK are not involved in PT-induced MLC2 activation. A,B: Involvement of 
MLCP (A) and MLCK (B) in terms of MLC2 activation was analyzed by Western blotting. A: Confluent 
HUVECs were either pre-treated with vehicle control (Co) for 120 min or for 5, 15, 30, 60 and 120 min with 
300 nM PT. Afterwards MLCP activation was analyzed using an specific anti-MYPT1 antibody. B: Confluent 
HUVECs were pre-treated with the MLCK inhibitor ML-7 (10 µM, 30 min) followed by PT treatment (300 nM, 1 
h). MLCK involvement was determined using an di(Thr18/ser19)-phosphorylated MLC2 antibody (downstream 
target of MLCK). One representative blot out of three is shown, each. 
 
3.2.1.4 ROCK 
A second possibility to induce MLC activation is via the Rho kinase (ROCK), which 
phosphorylates MLC at Ser19 and, therefore, leads to a direct MLC activation. To 
determine whether the actin response or the MLC activation were mediated by ROCK, we 
pre-treated HUVECs with the ROCK inhibitor Y-27632 (Figure 29). PT-induced stress fiber 
formation was clearly reduced by this inhibitor and also MLC(Thr18/Ser19) activation was 
completely prevented. 
 
Figure 29  PT-induced actin stress fiber formation and MLC activation depends on ROCK. 
Immunocytochemistry and confocal microscopy of F-actin (rhodamine phalloidine) and di-(Thr18/Ser19) 
phosphorylated MLC2 after treatment with vehicle control (1 h), with the ROCK inhibitor Y27632 (10 µM, 1 h), 
with 300 nM PT (1 h) or in combination with Y27632 (10 µM, 30 min pre-treatment) plus PT (300 nM, 1 h). 
One representative experiment out of three is shown. Scale bar represents 50 µM. 
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To prove if the PT-mediated hyperpermeability was also reduced, we measured 
impedance via the xCELLigence System (i.e. permeability, see 2.6.1). We treated 
HUVECs either with the ROCK inhibitor for 30 min, or with 300 nM PT, or in combination 
(30 min Y27632 followed by PT treatment). Indeed, quantification at time point 1.5 h upon 
PT treatment revealed that pre-treatment with the ROCK inhibitor partially reversed the 
PT-induced decrease in impedance.  
Figure 30  PT triggers hyperpermeability via ROCK. HUVECs were seeded on gold electrodes, grown 
to confluence and treated either with Y27632 (10 µM), with 300 nM PT or in combination (30 min Y27632 
followed by PT). Quantitative analysis of impedance sensing was performed at time point 1.5 h after PT 
treatment. Data is expressed as normalized cell index, a dimensionless parameter derived from the measured 
impedance changes. PT mean ± S.E.M. *P ≤ 0.05 vs. control (n = 1). 
 
Thus, we could show that ROCK plays a central role in the PT-induced signaling pathway. 
Furthermore, we observed RhoA activation and subsequent MLC phosphorylation within 1 
h PT treatment, which perfectly correlates with microtubule depolymerization described in 
chapter (3.1.1.). Therefore, we assume that a link between microtubule depolymerization 
and RhoA-ROCK-MLC pathway activation exist.   
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3.2.2 Involvement of MAPK pathways  
Besides the Rho pathway, mitogen-activated protein kinases (MAPKs) (p38, c-Jun N-
terminal kinases (JNK) and extracellular regulated kinase (ERK1/2)), are known to be 
involved in stress fiber formation and hyperpermeability113. By Western blot, we could 
show that JNK (Figure 31 B) and p38 MAPK, as well as its downstream target heat shock 
protein 27 (HSP27; Figure 31 A) were phosphorylated (i.e. activated) within 30 min upon 
PT treatment, whereas ERK1/2 was not affected (Figure 31 C).  
 
Figure 31  PT activates JNK and p38 MAPK but not ERK1/2. A-C: Confluent HUVECs were either pre-
treated with vehicle control (Co) or with 300 nM PT for 5, 15, 30, 60 and 120 min. Activation of p38 MAPK, 
HSP27, JNK and ERK1/2 were analyzed by Western blotting using specific antibodies. One representative 
experiment out of three is shown each.  
 
3.2.3 p38 MAPK and JNK 
In the next step we focused on p38 MAPK and JNK. Both are described to be activated 
upon microtubule depolymerization,114-117 however, only p38 MAPK is known so far to be 
involved in microtubule-associated actin remodelling and hyperpermeability in endothelial 
cells.114, 115 To investigate the role and importance of both MAPKs in terms of actin 
alterations upon PT treatment, we used specific inhibitors for p38 MAPK (SB203580, 
Figure 32 A) and JNK (SP600125, Figure 32 B). Interestingly, although we prove 
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functionality of the inhibitors (data not shown), they could not prevent the PT-induced actin 
stress fiber formation, cell retraction and gap formation.  
 
Figure 32  MAPK inhibitors SB203580 and SP600125 could not prevent stress fiber formation upon 
PT treatment. A,B: Immunocytochemistry and confocal microscopy of F-actin (rhodamine phalloidine) after 
treatment with vehicle control (1 h), with the p38 MAPK inhibitor SB203580 (20 µM, 1 h, A), with the JNK 
inhibitor SP600125 (25 µM, 1 h, B), with 300 nM PT (1 h) or in combination. One representative experiment 
out of three is shown. Scale bar represents 50 µM.  
 
To elucidate the effects on endothelial permeability, we measured impedance as 
described above (3.1.3.1). We pre-treated confluent HUVECs for 30 min with the p38 
MAPK inhibitor SB203580. Followed by a treatment with 100 and 300 nM PT. As 
expected, similar to the control (red line), single treatment with the inhibitor (pink line) did 
not influence the permeability and combination treatment with the inhibitor plus PT did not 
prevent the observed decrease in impedance (i.e. increase in permeability; cyan vs. green 
line and purple vs. blue line). However, compared to single PT treatment, the onset of 
hyperpermeability was shifted to later time points.  
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Figure 33 p38 MAPK is not involved in PT-mediated hyperpermeability. HUVECs were seeded on 
gold electrodes, grown to confluence and treated either with SB203580 (20 µM), with 100 and 300 nM PT or in 
combination (30 min SB203580 followed by PT). Data is expressed as normalized cell index, a dimensionless 
parameter derived from the measured impedance changes (PT mean ± SEM, n = 3). 
 
3.2.4 Involvement of intracellular calcium [Ca2+]i 
Since a rise in cytosolic Ca2+ has been established as the initial and pivotal signal that 
precedes endothelial contraction, junction disruption and hyperpermeability, we tested 
whether cytosolic calcium levels were affected by PT treatment. Therefore, HUVECs were 
pre-treated with Fura-2-AM (30 minutes 2 µM). Afterwards, 300 nM PT was added and 
[Ca2+]i levels were recorded for 45 minutes (Figure 34). To obtain a positive calcium signal 
and to confirm that cells are still alive, 10 µM histamine was added at time point 45 
minutes and data were recorded for further 10 minutes. We could not detect any changes 
in cytosolic calcium levels upon PT treatment, suggesting that calcium does not play a 
role in PT-triggered signaling. 
0 10 20 30 40 50 60
Histamine
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
R
a
tio
 
F3
40
/F
38
0
Time [min]
Control
300 nM PT
0 10 30 40 50
3  RESULTS 61 
Figure 34  PT does not affect intracellular calcium levels. The change of intracellular Ca2+ [Ca2+]i was 
monitored using confluent HUVECs which were pre-incubated with FURA-2-AM for 30 min. After replacing 
FURA-2-AM by HEPES cells were treated for 45 min with 300 nM PT (grey line) or were left untreated (black 
line). At the end, histamine (100 µM) was added as positiv control and were recorded for further 10 min. One 
representative figure out of three is shown. 
 
 
In summary, we suggest that the cellular effects (i.e. actinomyosin contraction, junction 
disassembly and hyperpermeability) of PT are mainly mediated by the RhoA/ROCK/MLC2 
pathway, whereby ROCK plays a pivotal role. In contrast, MLCK, MLCP, p38 MAPK, JNK 
or calcium seem to be not involved. The proposed signal pathway induced by PT is shown 
below (Figure 35). 
 
Figure 35  Proposed signal pathway leading to cellular effects upon PT treatment. Microtubule 
dissasembly activates RhoA, which in turn activates ROCK. Direct phosphorylation of MLC via ROCK triggers 
actomyosin-mediated contraction, junction disruption and hyperpermeability. JNK and p38 MAPK are also 
activated, however they are not essential for the PT induced cellular effects. Green: affected by PT, grey: not 
affected by PT. Dotted arrow line indicates no direct interaction.  
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3.3 Single dose treatment with PT selectively affects 
tumor vasculature in vivo  
The selective and fast shut down of blood flow in established tumor vessels is the main 
and most important hallmark of VDAs.70, 72 Therefore, we aimed to elucidate if PT is able 
to reduce tumor blood flow in vivo. We analyzed vessel quantity and perfusion as well as 
tumor histology upon single dose treatment with PT by using two different animal models. 
3.3.1 Determining the maximum tolerated dose (MTD) of PT 
Before we started with the in vivo tumor models we determined the MTD of PT. We 
systematically tested four different dosages of PT (1, 10, 30 and 50 mg/kg; Figure 36) that 
were IV injected into the tail vein of female C57BL/6 mice. We measured the mouse 
weight (indicator of health) every day up to 8 days. 1 and 10 mg/kg PT were well tolerated 
and there was no difference compared to control mice. In contrast, mice treated with 30 
and 50 mg/kg PT showed loss of weight and were apathetic. Therefore, a concentration 
between 10 and 30 mg/kg is suggested as the MTD of PT. 
Figure 36 In vivo evaluation of the MTD of PT. Female C57BL/6 mice were treated with different 
concentrations of PT (1, 10, 30, and 50 mg/kg; IV into the tail vein). To monitor the state of health, mouse 
weight was measured every day up to 8 days after PT injection. 1 and 10 mg/kg PT was well tolerated, 
whereas 30 and 50 mg/kg was not tolerated and the experiment had to be stopped early. Data are expressed 
as mean ± S.E.M (n = 4, 1 mg/kg) and (n = 5, control, 10, 30 and 50 mg/kg). For clarity, the mouse weight of 
control mice was normalized to 1. 
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3.3.2 PT selectively diminished tumor blood flow in a hamster 
dorsal skinfold chamber model 
We elucidated the capability of single dose treatment with PT to reduce tumor blood flow 
in a hamster dorsal skinfold chamber model, bearing hamster A-Mel-3 amelanotic 
melanomas (for details see 2.11.3). We simultaneously analyzed tumor blood vessels 
within the melanoma, and ‘normal’ blood vessels of the surrounding healthy tissue. FITC-
labeled dextran was injected IV to visualize blood perfusion and to determine the baseline. 
Upon IV injection of 10 mg/kg PT, we observed first perfusion irregularities in tumor blood 
vessels after 30 minutes (data not shown), which were clearly detectable after 2 h (Figure 
37 A, arrowheads, lower panel). In contrast, blood perfusion of ‘normal’ vessels was not 
affected (Figure 37 A, upper panel). Additionally, we quantified the velocity of red blood 
cells, the diameter of the vessels, and the functional vessel density. All three parameters 
were significantly reduced in tumor blood vessels compared to non-tumor blood vessels 
(Figure 37 B). Treatment with vehicle control (5% DMSO) did not reduce these 
parameters, neither in tumor nor in ‘normal’ blood vessels (Figure 37 C). 
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Figure 37  Single dose of PT selectively reduces tumor blood flow, tumor vessel diameter and 
functional tumor vessel density. A: Hamster A-Mel-3 amelanotic melanoma tumors were grown 2-D in 
hamster dorsal skinfold chambers. FITC-dextran (MW 500 kDa) was pre-injected IV 5 min before PT injection 
(10 mg/kg) to visualize tumor and healthy microcirculation and to determine the baseline. Every 30 min up to 2 
h, 30 s were recorded on digital video tape. Upon 2 h PT injection, normal tissue appears to be not affected, 
whereas tumor tissue showed regions of lesser perfusion, indicated by the arrowheads. One representative 
image of intravital microcopy is shown. B, C: Five regions of interest per tumor and normal tissue were 
selected upon PT (B) and DMSO (C) treatment to perform quantitative analysis of microcirculation parameters 
over a time period of 2 h. Red blood cell velocity (vRBC) [mm/s], vessel diameter (D) [µm] and functional 
vessel density (fvd) [cm/cm2] were evaluated offline by an image analysis system. *P, ≤ 0.05 versus muscle 
tissue (PT n = 6, DMSO n = 3).  
 
3.3.3 PT reduces tumor vessel perfusion without affecting the 
density of tumor vessels in an ectopic B16-F1 mouse 
melanoma tumor model 
To determine whether single dose treatment with PT causes tumor cell death due to tumor 
blood-flow shutdown we used highly vascularized B16-F1 mouse melanoma tumors (for 
details see 2.11.4), which grew subcutaneously in the hind limb of C57BL/6 mice. When 
tumors reached a size of approx. 650 mm3, we injected IV 10 mg/kg PT or 5% DMSO 
(vehicle control). 24 h later Hoechst 33342 was IV injected as perfusion marker, and mice 
were sacrificed after 1 min. Both, the tumor rim as well as the tumor center of PT- or 
vehicle-treated mice were analyzed (Figure 38). In control tumors, Hoechst 33342 
fluorescence (i.e. perfusion) was detectable nearly in equal intensity at the rim as well as 
in the center, whereas PT-treated tumors showed a lesser Hoechst 33342 intensity at the 
rim and almost no staining in the center (Figure 38 A,B). In contrast, CD31 positive 
endothelial cells were similarly distributed throughout the tumors, indicating that tumor 
vessel density was not altered by PT (Figure 38 A,C).  
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Figure 38  Single dose of PT significantly reduces Hoechst 33342 perfusion in B16-F1 tumor 
centers, whereby vessel density was not affected. A: B16-F1 mouse melanoma cells were subcutaneously 
injected into the left hind limb of female C57BL/6 mice. If tumors reached a size of approx. 650 mm3, either 
DMSO control (5%, 24 h) or PT (10 mg/kg, 24 h) was injected IV. Hoechst 33342 (10 mg/kg) was used as 
perfusion marker and was injected IV 1 min befor tumor removal. After embedding in frozen tissue medium, 
cryosections of 10 µm were prepared and stained with an anti-CD31 antibody to visualize endothelial cells. To 
obtain an overview of the tumor tissue, phase-contrast images were additionally taken. Representative images 
of control and PT-treated tumor centers and rims are shown. Scale bar represents 200 µm. B, C: For 
quantification, thirteen pictures of the tumor center and rim of two different sections were taken to analyze the 
intensity of Hoechst 33342 fluorescence (B) and to count CD31-positive endothelial cells (C). *P, ≤ 0.05 
versus control (PT n = 8, DMSO n = 6).  
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3.3.4 PT induces enormous central necrosis in B16-F1 mouse 
melanoma tumors 
Haematoxylin and eosin staining (H&E) of the same tumors as described above (3.3.3) 
revealed that single dose treatment with PT resulted in enormous central necrosis (Figure 
39 A), which spanned almost 30% of the whole tumor area (Figure 39 B). Control tumors 
showed central necrosis as well, but only 5% of the whole tumor area were affected and 
could be ascribed to the big tumor size. 
Figure 39  Single dose of PT induces necrosis in B16-F1 tumor centers. A: B16-F1 mouse melanoma 
cells were subcutaneously injected into the left hind limb of female C57BL/6 mice. If tumors reached a size of 
approx. 650 mm3, either DMSO control (5%, 24 h) or PT (10 mg/kg, 24 h) was injected IV. After tumor 
resection, formalin-fixation and paraffin embedding sections of 5 µm were prepared and stained with H&E. 
Scale Bar: 400 µm. B: Two sections per tumor were photographed using 4x magnification as described in the 
materials and methods section (2.10.3.2). Quantification of necrotic tumor areas was performed using ImageJ 
software. *P, ≤ 0.05 versus control (PT n = 9, DMSO n = 6). 
 
Taken together, we clearly could show in two different tumor models that single dose 
treatment with PT induces a rapid and selective shut-down of tumor blood flow and 
reduces Hoechst 33342 perfusion in vivo, whereas the overall vessel density was not 
affected. As a result, massive tumor cell necrosis in tumor centers occurred.  
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3.4 Multiple dose treatment of PT decelerates tumor 
growth in vivo  
To evaluate the therapeutical efficiency of PT, we used the same tumor model as 
described above (3.3.3), but PT treatment started as soon as tumors reached a size of 
about 90 mm3. 10 mg/kg PT was applied IV into the tail vein on day 0, 3 and 6, and we 
determined the overall capacity of PT to affect tumor growth and its tolerability. We 
observed that the increase in tumor growth was strongly diminished by PT compared to 
control tumors (Figure 40 A) and that the repeated application of PT was well tolerated 
since no significant change of mouse weight was measurable (Figure 40 B). 
Figure 40  Multiple dose treatment with PT decelerates tumor growth. A: B16-F1 mouse melanoma 
cells were subcutaneously injected into the left hind limb of female C57BL/6 mice. When tumors reached a 
size of approx. 90 mm3, either DMSO control (5%) or PT (10 mg/kg) was injected IV on day 0, 3 and 6 
(indicated by red arrows). Increased tumor size was assessed as described in the Materials and Methods 
section (2.10.4) and is displayed as x-fold increase in tumor volume compared to the starting point (0 d). *P, ≤ 
0.05 versus control (PT n = 6, DMSO n = 5). B: Mouse weight was measured every day to monitor tolerability 
of PT. 
 
This result demonstrates that multiple dose treatment with PT was well tolerated and led 
to a significant impairment of tumor growth in vivo. Although we assume that the observed 
effect was not exclusively mediated through the vascular disrupting potential of PT (also 
anti-angiogenesis and tumor growth-inhibiting effects are involved), we suggest that the 
potential of PT as a VDA may play an important part in this context.  
 
In summary, we clearly demonstrated by using in vitro, ex vivo and in vivo 
experiments that PT exhibits strong vascular disrupting actions.  
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Vascular disrupting agents (VDAs) have gained importance in clinical trials since they 
represent an effective and additional way to conventional chemotherapy. However, the 
fact that only a few VDAs have overcome the pre-clinical status and have been introduced 
into clinical trials, indicate that there are many difficulties that need to be solved. Indeed, 
VDAs are effective below their maximum tolerated dose (MTD) and complement the anti-
vascular effects of angiogenesis inhibitors (AI), but they also show some disadvantages in 
terms of resistance, scheduling and side-effects. Therefore, it is pivotal for the 
development of the next generation VDAs to address these issues and to improve their 
potential benefits. In this regard, natural compounds with their huge variety of new 
structures offer a considerable source of potential new agents. 
In the present study we introduce pretubulysin (PT), a new synthetic accessible natural 
compound of myxobacterial origin that shows typical VDA hallmarks in endothelial cells in 
vitro as well as in different tumor models in vivo. Furthermore, it was well tolerated thus, 
representing a serious new candidate for further clinical evaluation. 
4.1 PT treatment elicits typical hallmarks of vascular 
disruption in ECs in vitro 
4.1.1 The impact of PT on microtubules 
It is well known that microtubule disassembly induced by VDAs (e.g. CA-4-P) or other 
microtubule destabilizers (e.g. nocodazole) leads to various tissue- and cell specific 
signaling responses. For instance, microtubule depolymerization in fibroblasts attenuates 
polarity and migration,118 whereas in neutrophils polarity and migration are induced.119 In 
endothelial cells, microtubule disassembly impairs proliferation16 and time-dependently 
correlates with RhoA-ROCK-MLC as well as with p38 MAPK activation. Both pathways 
are known to contribute to actin remodeling, cell contraction and increased vascular 
permeability. 80, 114, 115, 120 In the present study, we show that the novel tubulin degrading 
agent PT is able to directly target microtubules and induces concentration-dependent 
microtubule disassembly in a confluent HUVEC monolayer. This result confirms previous 
studies of Eirich et al.108 and Rath et al.,16 which demonstrated that PT directly binds to 
the β-tubulin subunit of microtubules and induces depolymerization in proliferating human 
microvascular endothelial cells (HMECs). In addition, we observed that PT-mediated 
microtubule depolymerization time-dependently correlates with an activation of RhoA, 
phosphorylation of MLC, actin stress fiber formation, junction disruption and with an 
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increase in permeability. These observed effects are typical for tubulin binding VDAs 
described in literature, which showed that microtubule depolymerization seems to be the 
trigger.80 
4.1.2 The link between PT-mediated microtubule 
depolymerization and actin stress fiber formation 
The exact mechanism how microtubule depolymerization is linked to actin remodeling is 
not completely investigated so far. However, the fact that PT-mediated microtubule 
disruption correlates with RhoA activation let us speculate that it could be mediated 
through guanosine nucleotide exchange factors (GEFs) that are linked to microtubules.121, 
122
 GEFs together with GDP-dissociation inhibitors (GDIs) and GTPase-activating proteins 
(GAPs) regulate the activity-status of small GTPases like Rho, Rac, and Cdc42. Recent 
studies showed that GEF-H1, a Rho specific GEF, is inactive when it is bound to 
microtubules, whereas depolymerization results in its release and activation, accompanied 
by induction of stress fiber formation and MLC phosphorylation.79 Since these effects are 
also obvious upon PT treatment, we hypothesize that GEF-H1 might be involved.  
Among several RhoA targets it is known from previous work that microtubule targeting 
agents induce MLC phosphorylation and actin remodeling leading to endothelial 
hyperpermeability by a RhoA dependent activation of Rho kinase (ROCK).80, 120, 123 
Thereby, the binding of Rho-GTP to ROCK facilitates interactions of ROCK with target 
proteins (e.g. MLC) and regulates the translocation of the protein complex to the target 
side.124 By using a specific ATP-competitive ROCK inhibitor (Y27632) we could show that 
PT-mediated stress fiber formation as well as MLC phosphorylation were reduced. This 
result indicates an important role of ROCK.  
Besides the direct phosphorylation of MLC at Ser19, it is also possible that ROCK 
indirectly acts on MLC via phosphorylation of the regulatory subunit (MYPT-1) of myosin 
light chain phosphatase (MLCP). In case of phosphorylation, MYPT-1 dissociates from 
myosin and MLCP activity is inhibited.123 We used a side-specific antibody to phospho-
MYPT-1 (Thr696) and could show that PT-induced ROCK activity does not increase 
MYPT-1 phosphorylation. This result suggests that PT-mediated activation of MLC only 
occurs through direct interaction of ROCK.  
The counterpart of MLCP, in terms of MLC phosphorylation and activation, is MLCK. Its 
activity is mainly regulated by the calcium binding protein calmodulin, which binds in the 
presence of Ca2+ to the calmodulin binding domain and release autoinhibition. This in turn 
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leads to MLC phosphorylation at Ser19 and Thr18, which causes a shift in the tertiary 
protein structure of MLC and increases actinomyosin contraction. Although the 
contribution of intracellular Ca2+ is controversy discussed and some microtubule binding 
VDAs and destabilizing MTA act without affecting MLCK,80, 120, 123 we proved an eventual 
involvement by using the specific MLCK inhibitor ML-7, and additionally performed 
intracellular Ca2+ measurements. As supposed, PT treatment neither affects MLCK nor 
alters intracellular Ca2+ levels. Thus, strengthens our hypothesis that the observed cellular 
effects are directly mediated via the RhoA-ROCK-MLC pathway. 
4.1.3 PT and the microtubule mediated process of membrane 
blebbing  
Besides the RhoA-ROCK-MLC pathway, it is also known that actin remodeling and 
hyperpermeability, triggered by microtubule disassembly, could be mediated through 
mitogen-activated protein kinases (MAPKs).125 Thereby, especially p38 MAPK, a known 
important regulator of actin remodeling,126, 127 was reported to be involved in the action of 
microtubule disrupting compounds114, 115 and mediates, via HSP27, stress fiber 
formation.126 In fact, we could show that JNK and particularly p38 MAPK as well as its 
downstream target HSP27 were strongly phosphorylated by PT. However, treatment with 
specific inhibitors revealed that activation of p38 MAPK and JNK are not needed to 
mediate the effects of PT in our system. This observation differs completely from other 
known microtubules targeting agents, which use the p38 MAPK pathway in addition to the 
RhoA-ROCK-MLC pathway.114, 115 We speculate that the PT-induced activation of p38 
MAPK might be associated with the process of early membrane blebbing, which was 
observed at higher concentrations of PT after long-term treatment (data not shown). Early 
membrane blebbing was intensively described by a study of Kanthou and Tozer80, in 
which they could show that membrane blebbing occurred upon the disruption of 
microtubules. This phenomenon depended on the activation of p38 MAPK, but was 
independent of MLCK-mediated MLC phosphorylation and, remarkably, of apoptotic 
blebbing.80 The underlying mechanisms of how p38 MAPK control membrane blebbing 
are not clear, but involvement of HSP27, RhoA, and ERK are discussed.128 Furthermore, 
membrane blebbing was not observed in either smooth muscle cells or fibroblasts, in 
which CA-4-P, the lead VDA, induced stress fibers. This selectivity possibly reflects 
differences in regulation and composition of cytoskeletal systems in ECs.129 
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In addition to the classic p38 MAPK pathways inducing stress fiber formation, 
hyperpermeability and membrane blebbing, it is conceivable that p38 MAPK directly 
influences microtubules. For instance, tau, a microtubule associated protein, stabilizes in 
its unphosphorylated form microtubules and promote their assembly. Due to 
phosphorylation at multiple Ser/Thr sites by a number of kinases including p38 MAPK, 
tau-mediated stabilization is diminished, and microtubule depolymerization occurs.130 It is 
imaginable that PT-mediated activation of p38 MAPK on the one hand induces membrane 
blebbing, and on the other hand promotes additional microtubule depolymerization via 
positive feedback mechanisms. However, this assumption needs to be further evaluated. 
4.1.4 The influence of PT on endothelial junctions 
Besides morphological changes, a further major consequence of VDA treatment involves 
the maintenance of endothelial barrier integrity. It is known from previous studies, 
describing VDA action (e.g. CA-4-P) that increased paracellular permeability is one of the 
earliest effects that occur in endothelial cells in vitro80 and in tumor vasculature in vivo.72 
This phenomenon was also observed for PT, which concentration-dependently increased 
permeability within 30 minutes in cultured EC and led to an enormous FITC-dextran 
extravasation in tumor vessels. Interestingly, in vitro, the rise in permeability could partially 
be inhibited by using the ROCK inhibitor Y27632, suggesting a link between the signal 
pathways associated with PT action, morphological EC changes and functional properties 
of the endothelial barrier. The latter is regulated by adherens junctions, especially 
vascular endothelial (VE) cadherin, and tight junctions consisting of claudin-5, which 
represent the most important junction proteins to control permeability. In the present study 
we demonstrated that within 1 h PT treatment, VE-cadherin as well as claudin-5 was 
disrupted and huge intracellular gaps occurred. At the same time we observed an 
increase in permeability and cell contraction, indicating a link between junction disruption, 
hyperpermeability and actinomyosin contraction. In literature, internalization and cleavage 
of VE-cadherin, as well as tyrosine phosphorylation via SRC or Rho-GTPases, are 
intensively discussed to impair junction integrity, however, the specific consequences 
regarding vascular permeability are still unknown.110 Since PT-mediated cellular effects 
occur within minutes, we suggest that VE-cadherin modifications as described above 
might be too slow to explain the rapid effect of PT. Therefore, we assume that the 
observed increase in permeability is mediated by actinomyosin that is coupled to the 
catenin complex of VE-cadherin. In this case, PT treatment would trigger cell contraction 
via stress fiber formation, which in turn alters VE-cadherin organization and promotes 
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intracellular gap formation. According to this hypothesis, removal of PT causes 
reestablishment of a normal EC monolayer with intact junctions and relaxed actin fibers 
(data not shown), indicating that VE-cadherin reorganization occurs temporarily and 
seems to be actinomyosin dependent.  
In addition, it is known that VE-cadherin regulates by using the phosphatidylinositol-3-OH 
kinase PI(3)K-AKT-FoxO-pathway the expression of claudin-5 and influences 
angiogenesis.131 Thus, it is conceivable that PT-triggered VE-cadherin disruption also 
affects this pathway. Possibly, VE-cadherin destruction is associated with reduced 
phosphorylation of the pro-survival signaling of the kinase AKT, which in turn activates 
members of the FoxO transcription factors. As a result FoxO translocates to the nucleus 
and inhibits claudin-5 expression. This hypothesis would be in agreement with our results 
showing that VE-cadherin and claudin-5 junction disruption occurred in a similar way. 
Furthermore, a previous study by Vincent et al.132 demonstrated that the lead VDA CA-4-P 
also disrupts VE-cadherin, which was associated with reduced AKT phosphorylation. 
Actually we have not focused on AKT signaling in this study, hence, this point is still an 
assumption and requires further investigations. 
4.1.5 Cytotoxic profile of PT treatment in confluent ECs  
The cytoskeletal rearrangements, which occurred upon PT treatment affected not only the 
endothelial barrier function but also led to enormous cell shape changes and disruption of 
established tubes, suggesting that PT might be toxic to HUVECs. Cytotoxicity assays, 
however, revealed that PT neither considerably reduces metabolic activity nor induces 
apoptosis or necrosis after 24 h treatment. Furthermore, we could not detect any G2/M 
arrest, which plays an important role in the onset of apoptotic cell death. Our findings are 
in contrast to data from previous studies, in which PT as well as the lead VDA CA-4-P was 
shown to induce G2/M arrest and apoptosis within 24-48 h.16, 66, 133 The reason for this 
different result may be due to the fact that we worked with confluent, quiescent HUVECs, 
whereas the mentioned studies used proliferating ones, which are susceptible to the 
blockade of the spindle apparatus. This assumption is supported by own experiments 
showing that proliferating HUVECs pre-treated with PT show a four times higher induction 
of apoptosis and G2/M arrest than confluent ones (data not shown). Confluent HUVECs 
treated with CA-4-P also did not undergo metabolic changes, G2/M arrest, apoptosis or 
necrosis (data not shown). Toxicity studies by Dark et al.70 confirmed our hypothesis, but 
the reason why proliferating cells are more sensitive to treatment is not fully understood. 
4  DISCUSSION 74 
Moreover, HUVECs are even able to reassume their normal morphology after withdrawal 
of PT indicating that treatment is not cytotoxic. 
4.2 PT selectively targets tumor vasculature in vivo 
4.2.1 Mechanisms leading to selective blood flow shutdown  
By using different in vivo tumor models, we showed that PT treatment induces within 2 h a 
significant reduction in tumor blood perfusion, whereby perfusion of ‘normal’ (healthy) 
tissue seems to be not affected. These events are highly characteristic for tubulin-binding 
VDAs as previously described for CA-4-P.73, 134 We can not exclude that ‘normal’ blood 
vessels are not at all affected by PT, but we suggest that a mature endothelium covered 
by pericytes is more stable and, thus, resistant to PT treatment. This hypothesis is also 
based on previous data, which showed that in vitro co-culture of HUVECs with smooth 
muscle cells are lesser affected than ECs alone.132 Additionally, differences between 
tumor and ‘normal’ vasculature in regard to structure, organization, blood flow, 
permeability, interstitial fluid pressure, proliferation rate or modifications of tubulin and 
actin between tumor- and normal vasculature could contribute to the selectivity observed 
for PT, but are still a matter of debate.5, 135 Upon PT treatment, tumor vessel perfusion 
was significantly reduced in tumor centers and was accompanied by necrosis. 
Interestingly, the distribution of endothelial vessels seems to be not affected and 
independent of treatment. This suggests that vessels in the tumor center are much lesser 
perfused, possibly due to constriction or local occlusion by red blood cells, which might 
occur through endothelial cell shape changes or blebbing.67 It is also conceivable that the 
reduced blood velocity caused by PT might contribute to radial movements of erythrocytes 
far away from the main direction of flow. This enhances collisions and leads to the 
stacking of red blood cells, thereby evoking an increase in blood viscosity that further 
facilitates vessel occlusion (Figure 41).134 An increase in hypoxia, as it is described for 
CA-4-P, may additionally promote tumor cell death via increased production of vasoactive 
mediators (e.g. endothelin), however, this point has not been investigated so far (Figure 
41).  
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4.2.2 Therapeutic potential of PT 
Besides the single dose schedule, we also wanted to mimic a more therapeutical setting. 
We injected PT metronomically (three times, every third day) and measured tumor size as 
well as mouse weight. Although this model does not allow to discriminate between effects 
of PT on cancer cells and on the tumor vasculature, the strong tumor growth-decelerating 
action of PT clearly demonstrates the overall anti-cancer potential of the compound. 
Importantly, PT seems to be well tolerated since no obvious side effects were detected 
and the animals did not exhibit significant weight changes. In summary, compared to other 
xenograft studies,66, 70 PT shows comparable effects in terms of blood flow shut-down, 
induction of necrosis and overall anti-tumor activity, although a ten times lower 
concentration was used. These aspects, plus the good tolerance, let us suggest that PT 
might be a novel interesting candidate for further preclinical and clinical testing. 
4.2.3 Possible adverse effects of PT treatment 
Despite the fact that PT, like other VDAs, causes extensive tumor necrosis, it is important 
to keep in mind that the deficiency in oxygen on the one hand induces tumor cell death, 
but on the other hand also may stimulate signal pathways that promote angiogenesis.128 
The latter consequence might be the main reason why single treatments with VDAs still 
fail to prevent tumor regrowth.81 For instance, hypoxia, which mainly occurs upon vessel 
occlusion, is a strong inducer of hypoxia-inducible factor (HIF)-1α and related to 
angiogenic gene expression. In literature, it was shown that CA-4-P induces a strong 
expression of HIF-1α in cultured ECs, which undoubtably activates angiogenic 
pathways.135 Additionally, endothelial progenitor cells, which are mobilized from the bone 
marrow upon VDA treatment, specifically home into the supplying mother vessels and can 
also contribute to angiogenic activity.136 Therefore, CA-4-P treatment is still used in 
combination with other chemotherapeutic agents or AI that inhibit neovascularization. In 
this regard, scheduling and the succession of VDA application are very important to obtain 
tumor control.83-85 Indeed, we cannot say whether PT treatment induces such signaling 
cascades leading to angiogenic activity, however, the possibility exists and should be kept 
in mind when tumors are treated with PT.  
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The proposed mechanism for the shut-down in tumor blood flow after treatment with PT is 
shown below (Figure 41). 
 
Figure 41 Mode of action of PT on ECs and on tumor vasculature. Microtubule dissasembly activates 
the RhoA/ROCK/MLC pathway as well as the p38 MAPK pathway. Both evoke actin stress fiber formation and 
EC contraction. As a result, endothelial junctions are disrupted and permeability increases. At the end, 
reduced blood flow and tumor cell death induced by necrosis occur. The dashed and grey arrows indicate 
potential additional pathways activated by PT, however, these were not investigated. EC: endothelial cell.  
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Vascular disrupting agents (VDAs), in contrast to angiogenesis inhibitors (AI), selectively 
target the established tumor vasculature of larger solid tumors. They rapidly (within 
minutes) induce vessel occlusion and blockage of blood flow followed by tumor necrosis. 
Within the class of VDAs, natural compounds, that induce microtubule depolymerization in 
ECs are the most successful VDAs tested in clinical trials today. Unfortunately, the 
number of drug candidates is still limited and some compounds suffer from severe side 
effects. Thus, there is still a great need to advance this promising field by discovering and 
characterizing new substances.  
In the present study we evaluated pretubulysin (PT), a novel myxobacterial compound, 
which represents a biosynthetic precursor of the microtubule depolymerizing peptide 
tubulysin. Structurally, PT is a linear tetrapeptide and synthetically fully accessible. It 
shows nearly the same tubulin degrading activity than tubulysin and also its anti-
angiogenic activity as well as its potential to inhibit tumor cell growth was intensively 
investigated in previous studies. Since PT showed already profound anti-vascular and 
microtubule targeting properties in proliferating ECs, we hypothesized that PT also might 
have vascular disrupting potential in a quiescent endothelium. Therefore, we performed 
an in-depth characterization of this agent, both in vitro and in different in vivo tumor 
models. 
Indeed, we could show for the first time that PT elicits typical hallmarks of vascular 
disruption in ECs. It rapidly (within 30 minutes) induces endothelial hyperpermeability, 
disrupts endothelial junctions, redistributes focal adhesions and destroys established 
endothelial tubes. In addition, PT-mediated tubulin depolymerization increases stress fiber 
formation and EC contraction by activation of the RhoA/ROCK/MLC pathway independent 
of MLCK, MLCP or calcium. In contrast to the available VDAs, p38 MAPK activation was 
not found to be involved. Even long-term treatment with PT did not induce biological 
relevant apoptosis, necrosis or metabolic activity changes, indicating that PT treatment 
was not cytotoxic. In vivo, a single dose of PT (10 mg/kg) significantly and selectively 
decreased blood flow and vessel diameter in tumors, but not in the neighboring healthy 
tissue. Additionally, single doses of PT caused enormous tumor cell necrosis within 24 h. 
Repeated PT doses strongly decelerated tumor growth and were well tolerated.  
In conclusion, we demonstrated that PT exerts strong vascular disrupting activities in vitro 
and selectively impairs tumor blood perfusion in vivo, thereby being efficient at non-toxic 
doses. Its availability in larges scales provides the opportunity for chemical modification 
and optimization, which opens up the field for further investigations. Since PT exhibits 
prominent hallmarks of established VDAs that are tested in clinical trials, we assume that 
this natural compound represents a novel, promising pharmacological option for anti-
vascular tumor treatment. 
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